Reduced viral infection
Patent Information
- Application Number
- JP2023532329
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-07-02
- Filing Date
- 2021-11-25
- Publication Date
- 2024-12-03
AI Technical Summary
Current buffers used for inhalation and intranasal administration have not effectively reduced the replication of airborne viruses, particularly coronaviruses and influenza viruses, despite their ability to temporarily lower nasopharyngeal pH.
A composition comprising clove oil, eucalyptus oil, ginger oil, or their extracts, combined with a buffer and optionally zinc ions, bicarbonate ions, and transferrin, is administered via nasal spray, inhaler, or nebulizer to reduce viral replication by maintaining a neutral pH and inhibiting viral entry into host cells.
The composition effectively reduces viral replication of airborne viruses such as coronaviruses and influenza viruses by neutralizing the acidic environment in the nasal mucosa, preventing viral spike protein conformation changes and subsequent cell entry, thereby inhibiting infection.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Field of Invention The present invention relates to compositions comprising clove oil, eucalyptus oil, basil oil, ginger oil, extracts or components of any of these, or one or more of these in combination, and buffer compositions having a pH of 6.7 to 7.9 at a temperature of 37°C, for use both for the treatment, preventive treatment or recovery from wind-borne viral infections, or for reducing viral replication in subjects infected with wind-borne viruses or subjects exposed to wind-borne viruses that can cause wind-borne viral infections in subjects. The present invention also relates to aqueous compositions comprising either a buffer and an essential oil having antiviral, antibacterial or antifungal activity; or comprising a buffer, bicarbonate ions and zinc ions; or comprising a buffer, bicarbonate ions and transferrin and / or iron ions. The present invention also relates to methods for preparing compositions and concentrates of compositions.
[0002] The composition can be used in methods for treating, preventing, or recovering from a target wind-borne viral infection, and in methods for reducing viral replication in a subject infected with a wind-borne virus, or in a subject exposed to a wind-borne virus capable of causing a target wind-borne viral infection. Examples of wind-borne viruses include coronaviruses, such as RNA viruses including MERS-CoV, SARS-CoV, and SARS-CoV-2.
[0003] The composition can be administered by intranasal spray, inhaler or nebulizer, or in the form of a cream, gel or emulsion; therefore, the present invention also relates to intranasal sprays, inhalers, nebulizers, creams, gels or emulsions containing the composition. The composition can also be similarly applied to masks or other facial coverings that reduce the risk of viral infection from airborne viruses; therefore, the present invention also relates to nebulizers containing the composition. The composition can also be used in a container through which an oxygen-containing gas is passed for bubbling before being inhaled by the subject; therefore, the present invention also relates to containers containing the composition. [Background technology]
[0004] All viruses infect and multiply in living hosts by entering the host's body via a liquid carrier such as body fluids, sneeze secretions, or water droplets. Airborne viruses are viruses that are present in and transmitted by particles in exhaled air. These particles include aerosols, which have a diameter of less than 5 micrometers and can remain airborne for long periods, as well as larger droplets that can cause infection over relatively short distances. Airborne viruses include (i) RNA viruses such as coronaviruses (e.g., MERS-CoV, SARS-CoV, and SARS-CoV-2), influenza viruses (e.g., influenza A virus, influenza B virus, influenza C virus, and parainfluenza virus), rhinovirus, measles virus, mumps virus, rubella virus, and human respiratory syncytial virus, and (ii) DNA viruses such as parvovirus B19, adenovirus and adeno-associated virus, herpes viruses (e.g., varicella-zoster virus (VZV or HHV-3), Epstein-Barr virus (EBV or HHV-4), human herpesvirus 6 (HHV-6A and HHV-6B), and human herpesvirus 7 (HHV-7)), polyomaviruses (e.g., BK polyomavirus and WU polyomavirus) and poxvirus.
[0005] Airborne viruses enter the body via mucosal surfaces and, in particular, through the nasal cavity and other airway epithelial surfaces. The nasal cavity and other airway epithelium tend to be acidic and can become even more acidic, for example, due to gastroesophageal reflux.
[0006] The structural characteristics of the viral capsid are highly suitable for viral replication. This is because the capsid must contain and protect nucleic acid-containing material, be able to open into the outer membrane of the target cell, and provide a reliable pathway for inducing nucleic acid into the target cell. The spike protein on the capsid fulfills the latter two roles, mediating binding to the cell receptor and subsequent fusion of the virus with the cell membrane. A motif containing two 7-amino acid repeating regions and a hydrophobic fusion peptide (Dutch et al, Biosci Rep, 2000, vol 20(6), pages 597-612) is present in the SARS-CoV spike protein (Hakansson-McReynolds et al, J Biol Chem, 2006, vol 281(17), pages 11965-11971), in other coronaviruses (Xu et al, J Biol Chem, 2004, vol 279(47), pages 49414-49419), in influenza hemagglutinin (HA) (Skehel et al, Annu Rev Biochem, 2000, vol 69, pages 531-569), and in other viruses.
[0007] Viral infection is initiated when the viral spike protein binds to a specific receptor or co-receptor on the target cell surface, mediated by the receptor-binding domain (RBD) of the viral spike protein. Therefore, the RBD plays a crucial role in viral binding, fusion, and internal migration. Proteases found in the nasal cavity and other respiratory tract epithelium, coupled with an acidic environment, induce hydrolysis of the spike protein, causing a structural change that facilitates binding to the host cell membrane.
[0008] In influenza viruses, the hemagglutinin (HA) spike protein is a homotrimeric glycoprotein that binds to human mucosal epithelium and subsequently fuses its two segments. Cleavage activation of the HA precursor protein by protease enzymes is an essential step in the influenza virus replication cycle. HA cleavage activation is required for virus-endosomal membrane fusion and subsequent release of the influenza virus genome into the cytoplasm. Previous studies have suggested that HA cleavage is most likely facilitated by membrane-bound or extracellular trypsin-like proteases present in the airways (Hamilton, J Virol, 2012, vol 86(19), pages 10579-10586).
[0009] SARS-CoV-2, a new strain of coronavirus and the causative agent of the COVID-19 pandemic, was first identified in Wuhan, China in 2019. While the coronavirus spike protein differs from that of the influenza HA protein, the overall mechanism of viral cell attachment is similar, both requiring an acidic environment. Both coronaviruses and influenza viruses require an acidic environment in endosomes to induce fusion with their cell membranes and delivery of the viral nucleocapsid into the cytoplasm. Recently, SARS-CoV-2 has been shown to utilize host receptors, particularly angiotensin-converting enzyme 2 (ACE2), and host proteases for cell surface binding, preparation, and internal migration. ACE2 is a member of the M2 family of metallopeptidases and contains a HEXXH motif that functions as a zinc-binding domain in its active site (Speth et al, The Faseb Journal, 2014, https: / / doi.org / 10.1096 / fasebj.28.1_supplement.1067.4). The structure of the extracellular portion of the SARS-CoV-2 spike protein in the pre-fusion structure was recently published (Wrapp et al, Science, 2020, vol 367, pages 1260-1263), showing that the spike forms a trimer that binds to ACE2 on the host cell. Upon ACE2 binding in the acidic environment of endosomes, the spike changes from its pre-fusion to its post-fusion structure (preparation stimulus) as part of the cell entry process. Therefore, coronaviruses use their spike proteins for target cell selection and entry into target cells, while SARS-CoV-2 uses the ACE2 receptor for internal translocation and the cellular protease TMPRSS2 for preparation stimulation.
[0010] The envelope of the SARS-CoV virus also contains prominent protrusions formed by the spike protein, S (Li et al, J Virol, 2006, vol 80(14), pages 6794-6800). Similar to SARS-CoV-2, the SARS-CoV spike protein directs entry into cells by binding to the receptor ACE2 on the cell surface (Li et al, Nature, 2003, vol 426, pages 450-454) and by fusing the virus with the host membrane (Dave Cavanagh, The coronavirus surface glycoprotein, 1995, Plenum Press, New York). Several groups (Simmons et al, Antiviral Research, 2013, vol 100(3), pages 605-614) have identified cathepsins and type II transmembrane serine proteases as cell activators of SARS-CoV and have shown that certain newly emerging viruses may induce activation of spike proteins via these enzymes to promote their transmission, and that this is dependent on epithelial pH (Laporte et al, Current Opinion in Virology, 2017, vol 24, pages 16-24). Yang et al. (J Virol, 2004, vol 78(11), pages 5642-5650) reported that SARS-CoV cell entry is mediated by spike glycoproteins and enhanced by dendritic cell translocation via pH-dependent endocytosis. Wang et al. (Cell Research, 2008, vol 18, pages 290-301) reported that SARS-CoV enters host cells via clathrin-independent and caveolae-independent pathways. Yang et al. reported that the entry pathway is pH-dependent (Yang et al, J Virol, 2004, vol 78(11), pages 5642-5650) and requires an acidic environment in the host cell interstitial fluid.
[0011] The SARS-CoV-encoded protein, denoted as open reading frame-9b (ORF-9b), localizes to host cell mitochondria and induces mitochondrial elongation by inducing ubiquitination and proteasomal degradation of dynamin-like protein 1, a host protein involved in mitochondrial fission (Shi et al, J Immunol, 2014, vol 193(6), pages 3080-3089). Consequently, mitochondria are induced to increase ATP production, providing energy for viral replication (Moreno-Altamirano et al, Front Cell Infect Microbiol, 2019, vol 9, article 95), and as a result of this process, protons are released that lower the host cell's pH.
[0012] The infection process of many wind-borne viruses other than coronaviruses is similarly pH-dependent. These viruses include, for example, influenza virus (Seth et al, J Virol, 2003, vol 77(11), pages 6520-6527; Seth et al, J Virol, 2003, vol 77(1), pages 167-178; Tong et al, Virology, 2002, vol 301, pages 322-333; Skehel et al, Annu Rev Biochem, 2000, vol 69, pages 531-569), measles virus (Weiss et al, Am J Biochem & Biotech, 2013, vol 9(3), pages 243-254), rubella virus (Lee et al, Clin Microbiol Rev, 2000, vol 13(4), pages 571-587), and parvovirus B19 (Blumel et al, Transfus Med Hemother, 2010, vol 37(6), pages 339-350; adeno-associated viruses (Salganik et al, J Virol, 2012, vol 86(21), pages 11877-11885); adenoviruses (Baker et al, Sci Adv, 2019, vol 5(9), eaax3567); herpesviruses such as varicella-zoster virus (Finnen et al, J Virol, 2006, vol 80(21), pages 10325-10334; Girsch et al, J Virol, 2019, vol 93(17), e00505-19); polyomaviruses such as WU polyomavirus (Bhattacharjee et al, Can J Microbiol, 2017, vol 63, pages Examples include the 193-211) and the smallpox virus (Moss, Viruses, 2012, vol 4(5), pages 688-707).
[0013] Therefore, the process of wind-borne virus infection can be summarized as follows: 1. Wind-borne viruses (such as influenza viruses, rhinoviruses, or coronaviruses) are transmitted through water droplets or bodily fluids, enter the body via the nose, migrate to the nasal mucosa, and also pass through the pharynx and eyes. 2. The nasal mucosa is slightly acidic (pH 5.5-7.0), and can become even more acidic due to acid reflux from the stomach (GERD). 3. Protease enzymes found on cells in the nasal epithelium function optimally in highly acidic (pH < 3) or highly alkaline (pH > 9) environments, but their hydrolysis rates are slower at physiological pH (7.2–7.38). Proteases are selective (and the cellular protease TMPRSS2 protease selectively hydrolyzes coronavirus spike proteins). 4. The acidic environment of the nasal cavity epithelium / interstitial fluid alters the three-dimensional structure of spike proteins, which optimizes their binding to the host cell membrane. 5. Viral spike proteins bind to the cell membrane. In the case of influenza viruses, hemagglutinin (HA) or neuraminidase (NA) proteins bind to sialic acid on the cell membrane. In the case of coronaviruses, the spike protein strongly binds to the ACE2 dimer in the cell membrane. 6. Fusion of the virus with the cell, followed by endocytosis, occurs, which requires an acidic environment (pH < 5.5). 7. The viral cell envelope opens, releasing viral nucleic acids into the host cell, as well as signaling proteins, which disrupt mitochondria and other processes, enabling optimal nucleic acid transcription and daughter virus production.
[0014] Buffers have previously been used for inhalation and intranasal administration. For example, Diether et al. (Arzneimittelforschung, 1982, vol 32(4), pages 406-408) investigated the bronchodilating effects of phosphate and Tris (THAM) buffers administered by inhalation. Davis et al. (Respiratory Care, 2013, vol 58(7), pages 1226-1232) investigated the safety of alkaline glycine buffer administered by inhalation from the perspective of its potential use as a drug delivery carrier. Washington et al. (Int J Pharm, 2000, vol 198(2), pages 139-146) measured baseline human intranasal pH and investigated the effect of sodium chloride (0.9%) buffer at pH 7.2 or 5.8 and sorensen phosphate buffer (0.06M or 0.13M) at pH 5.8 or 5.0 on the pH of intranasal administration buffers. Gern et al. (The Journal of Infectious Diseases, 2007, vol 195, pages 1137-1143) showed that intranasal administration of a low-pH citrate / phosphate buffer temporarily lowered the surface pH of the human nasopharynx to approximately 4.0, inhibiting the replication of most human rhinoviruses and reducing influenza virus replication, but did not significantly reduce respiratory symptoms. However, to date, buffers with a neutral pH have not been used to reduce the replication of airborne viruses. [Overview of the project]
[0015] A first aspect of the present invention provides a composition comprising clove oil, eucalyptus oil, basil oil, ginger oil, an extract or component of any of these, or a combination thereof, for use in the treatment, preventive treatment or recovery from wind-borne viral infections, or for use in a subject infected with a wind-borne virus, or a subject exposed to a wind-borne virus that can cause an wind-borne viral infection in the subject.
[0016] In one embodiment of the first aspect of the present invention, the composition further comprises a buffer solution; typically, the composition comprises 1 to 500 mmol / L of buffer solution.
[0017] In one embodiment of the first aspect of the present invention, the composition is a composition comprising a solution, suspension, dispersion, mixture or emulsion, or microdroplets. In one embodiment of the first aspect of the present invention, the composition is an aqueous composition. In one embodiment, the composition is an aqueous solution, aqueous suspension, aqueous dispersion, aqueous mixture or aqueous emulsion, or an aqueous composition comprising microdroplets. In one embodiment, the composition is an aqueous emulsion or an aqueous composition comprising microdroplets.
[0018] A second aspect of the present invention provides an aqueous composition comprising: (i) 1 to 500 mmol / L buffer solution; and (ii) Essential oils or extracts or components having antiviral, antibacterial, or antifungal activity in an amount of 0.1 to 200 g / L.
[0019] In one embodiment of a second aspect of the present invention, the composition is for use in the treatment, preventive treatment or recovery from an airborne viral infection, or for use in a subject infected with an airborne virus, or a subject exposed to an airborne virus that can cause an airborne viral infection in the subject.
[0020] In one embodiment of the first or second aspect of the present invention, the composition is intended for use in the treatment, preventive treatment, or recovery from a wind-borne viral infection.
[0021] In another embodiment of the first or second aspect of the present invention, the composition is intended for use in reducing or preventing (typically reducing) viral replication in subjects infected with an airborne viral infection.
[0022] In further embodiments of the first or second aspects of the present invention, the composition is intended for use in reducing or preventing (typically reducing) viral replication in a subject exposed to an airborne virus that can cause an airborne viral infection in the subject.
[0023] In one embodiment of the first or second aspect of the present invention, the wind-borne viral infection is caused by a coronavirus selected from MERS-CoV, SARS-CoV, and SARS-CoV-2; typically, the wind-borne viral infection is caused by SARS-CoV-2.
[0024] In another embodiment of the first or second aspect of the present invention, the wind-borne viral infection is caused by an influenza virus selected from influenza A virus, influenza B virus, influenza C virus, and parainfluenza virus; typically, the wind-borne viral infection is caused by influenza A virus (such as H1N1).
[0025] In one embodiment of a second aspect of the present invention, the essential oil is selected from clove oil, eucalyptus oil, basil oil, ginger oil, saffron oil, hemp oil, tea tree oil, black seed oil, any extract or component thereof, or a combination thereof. Preferably, the essential oil is selected from clove oil, eucalyptus oil, basil oil, ginger oil, any extract or component thereof, or a combination thereof.
[0026] In one embodiment of the first or second aspect of the present invention, the oil is clove oil (Syzygium aromaticum). Typically, clove oil is extracted from clove flower buds, usually by steam distillation using water. Components of clove oil include eugenol, caryophyllene, ursolic acid, oleic acid (18:1 n-9), and linoleic acid (18:2 n-6).
[0027] In one embodiment of the first or second aspect of the present invention, the oil is eucalyptus oil (Eucalyptus globulus). Typically, eucalyptus oil is extracted from eucalyptus leaves, typically by steam distillation using water. Components of eucalyptus oil include eucalyptol, jensenone, ursolic acid, 1,8-cineole, α-pinene, palmitoleic acid (16:1 n-7), heptadecenoic acid (17:1 n-7), oleic acid (18:1 n-9), and linoleic acid (18:2 n-6).
[0028] In one embodiment of the first or second aspect of the present invention, the oil is basil oil (Ocimum basilicum). Typically, basil oil is extracted from basil leaves or seeds (typically basil leaves) typically using water, methanol, or ethanol (typically by steam distillation with water). Components of basil oil include eugenol, caryophyllene, estragole, 1,8-cineole, camphor, thymol, eugenol epoxide, apigenin, linalool, rosmarinic acid, ursolic acid, oleic acid (18:1 n-9), linoleic acid (18:2 n-6), and alpha-linolenic acid (18:3 n-3).
[0029] In one embodiment of the first or second aspect of the present invention, the oil is ginger oil (Zingiber officinale). Typically, ginger oil is extracted from ginger rhizomes, typically by steam distillation using water. Components of ginger oil include zingiberene, 6-gingerol, 6-shogaol, gingeronone A, α-curcumene, β-sesquiphellandrene, α-farnesene, α-phellandrene, β-phellandrene, camphene, β-bisabolene, ursolic acid, palmitoleic acid (16:1 n-7), oleic acid (18:1 n-9), linoleic acid (18:2 n-6), α-linolenic acid (18:3 n-3), arachidonic acid (20:4 n-6), and erucic acid (22:1 n-9).
[0030] In one embodiment of a second aspect of the present invention, the oil is saffron oil (Crocus sativus). Typically, saffron oil is extracted from the saffron flower and stigma. Components of saffron oil include crocetin, crocin, picrocrocin, safranal, and linoleic acid (18:2 n-6).
[0031] In one embodiment of a second aspect of the present invention, the oil is cannabis oil (Cannabis sativa). A preferred cannabis strain is the Jamaican Black Swan strain. Typically, cannabis oil is extracted from cannabis leaves. Components of cannabis oil include kafranone, tetrahydrocannabinol, cannabidiol, cannabinol, tetrahydrocannabivarin, linoleic acid (18:2 n-6), alpha-linolenic acid (18:3 n-3), and gamma-linolenic acid (18:3 n-6).
[0032] In one embodiment of a second aspect of the present invention, the oil is tea tree oil (Melaleuca alternifolia). Typically, tea tree oil is extracted from the leaves of the tea tree. Components of tea tree oil include 1,8-cineole, terpinen-4-ol, terpinolene, α-terpinene, γ-terpinene, p-cymene, α-pinene, α-terpineol, oleic acid (18:1 n-9), and linoleic acid (18:2 n-6).
[0033] In one embodiment of a second aspect of the present invention, the oil is black seed oil (Nigella sativa). Typically, black seed oil is extracted from the seeds of black cumin. Components of black seed oil include thymoquinone, oleic acid (18:1 n-9), and linoleic acid (18:2 n-6).
[0034] In one embodiment of the first or second aspect of the present invention, the essential oil extract or component is eugenol, zingiberene, eucalyptol, jensenone, ursolic acid, caryophyllene, estragol, 1,8-cineole, camphor, thymol, eugenol epoxide, apigenin, linalool, rosmarinic acid, 6-gingerol, 6-shogaol, gingerenone A, crocetin, crocin, picrocrocin, safranal, kafranone, tetrahydrocannabinol, cannabidiol (or its metabolites) Selected from monounsaturated or polyunsaturated fatty acids such as 7-hydroxycannabidiol, cannabinol, tetrahydrocannabivarin, terpinen-4-ol, terpinolene, α-terpineol, thymoquinone, α-curcumene, β-sesquiphellandrene, α-farnesene, α-phellandrene, β-phellandrene, camphene, β-bisabolene, α-terpinene, γ-terpinene, p-cymene, α-pinene, or palmitoleic acid, heptadecenoic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, arachidonic acid, or erucic acid.
[0035] In one embodiment of the first or second aspect of the present invention, the essential oil, or its extract or component, has antiviral activity.
[0036] In one embodiment of the first or second aspect of the present invention, the buffer solution comprises bicarbonate ions or equivalents thereof.
[0037] In another embodiment of the first or second aspect of the present invention, the buffer consists of or is based on (i) Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffers, urea, ionic liquid buffers, or combinations thereof, and (ii) bicarbonate ions or equivalents thereof. Typically, the buffer consists of or is based on the following: (i) Good buffers of 1 to 100 mmol / L, aminosulfonic acids, aminosulfinic acids, phosphoric acid, phosphate, heteroaryls, phenolic acids, amino acids, peptides, peptide equivalents, polymer buffers, urea, ionic liquid buffers, or combinations thereof; and (ii) Bicarbonate ions or equivalents in a concentration of 21 to 35 mmol / L.
[0038] In another embodiment of the first or second aspect of the present invention, the buffer comprises or is based on (i) one or more phosphates and (ii) bicarbonate ions. Typically, the buffer comprises or is based on KH2PO4, Na2HPO4 and NaHCO3.
[0039] In one embodiment of the first or second aspect of the present invention, the composition further comprises 0.1 to 200 μmol / L of zinc ions.
[0040] In one embodiment of the first or second aspect of the present invention, the composition further comprises 0.1 to 100 μmol / L of transferrin and / or iron ions.
[0041] In one embodiment of the first or second aspect of the present invention, the composition includes the following: (i) Buffer solution of 1 to 500 mmol / L; (ii) 0.1 to 50 g / L of clove oil or its extract or component; (iii) 0.1 to 50 g / L of eucalyptus oil or its extract or components; (iv) 0.1 to 50 g / L of basil oil or its extract or components; and (v) 0.1 to 50 g / L of ginger oil or its extract or component.
[0042] In another embodiment of the first or second aspect of the present invention, the composition includes the following: (i) Buffer solution of 1 to 500 mmol / L; (ii) Zinc ions in concentrations of 0.1 to 200 μmol / L; (iii) 0.1 to 50 g / L of clove oil or its extract or components; (iv) 0.1 to 50 g / L of eucalyptus oil or its extract or components; (v) 0.1 to 50 g / L of basil oil or its extract or components; and (vi) 0.1 to 50 g / L of ginger oil or its extract or component.
[0043] In another embodiment of the first or second aspect of the present invention, the composition includes the following: (i) One or more phosphoric acids in a concentration of 25-250 mmol / L; (ii) 1 to 45 mmol / L (preferably 21 to 35 mmol / L) of bicarbonate ions; (iii) 0.1 to 10 g / L of clove oil or its extract or components; (iv) 0.1 to 10 g / L of eucalyptus oil or its extract or components; (v) 0.1 to 10 g / L of basil oil or its extract or components; and (vi) 0.1 to 10 g / L of ginger oil or its extract or component.
[0044] In another embodiment of the first or second aspect of the present invention, the composition includes the following: (i) One or more phosphoric acids in a concentration of 25-250 mmol / L; (ii) 1 to 45 mmol / L (preferably 21 to 35 mmol / L) of bicarbonate ions; (iii) Zinc ions in a concentration of 0.1 to 50 μmol / L; (iv) 0.1 to 10 g / L of clove oil or its extract or components; (v) 0.1 to 10 g / L of eucalyptus oil or its extract or components; (vi) 0.1 to 10 g / L of basil oil or its extract or components; and (vii) 0.1 to 10 g / L of ginger oil or its extract or component.
[0045] In one embodiment of the first or second aspect of the present invention, the composition further includes the following: (i) Calcium ions and magnesium ions in a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 0.1 to 2.5 mmol / L; (ii) 2.5 to 20 mmol / L of potassium ions; (iii) Chloride ions in concentrations of 96-126 mmol / L; and (iv) 100-300 mmol / L of sodium ions.
[0046] In one embodiment of the first or second aspect of the present invention, the composition further comprises one or more additional components selected from NaCl, KCl, MgCl2, xylitol, EDTA, CaCl2, glycerol, HPMC, PEG400, poloxamer 188, benzalkonium chloride, and sodium hyaluronate.
[0047] In one embodiment of the first or second aspect of the present invention, the composition has a pH of 6.7 to 7.9 at a temperature of 37°C.
[0048] In one embodiment of the first or second aspect of the present invention, the composition is an aqueous solution, an aqueous suspension, an aqueous dispersion, an aqueous mixture, or an aqueous emulsion, or an aqueous composition comprising microdroplets. In one embodiment, the composition is an aqueous emulsion or an aqueous composition comprising microdroplets.
[0049] A third aspect of the present invention provides a buffer composition having a pH of 6.7 to 7.9 at a temperature of 37°C, for use in the treatment, preventive treatment or recovery from wind-borne viral infections, or for use in reducing or preventing viral replication in subjects infected with wind-borne viruses, or subjects exposed to wind-borne viruses that can cause wind-borne viral infections in subjects.
[0050] In one embodiment of a third aspect of the present invention, the buffer composition is for use in the treatment, preventive treatment, or recovery from an airborne viral infection.
[0051] In another embodiment of a third aspect of the present invention, the buffer composition is intended for use in reducing or preventing (typically reducing) viral replication in subjects infected with an airborne viral infection.
[0052] In a further embodiment of a third aspect of the present invention, the buffer composition is used to reduce or prevent (typically reduce) viral replication in a subject exposed to an airborne virus capable of causing an airborne viral infection of the subject.
[0053] In one embodiment of a third aspect of the present invention, the buffer composition is a solution, suspension, dispersion, mixture, or emulsion, or the buffer composition comprises microdroplets. In one embodiment of a third aspect of the present invention, the buffer composition is an aqueous composition. In one embodiment, the buffer composition is an aqueous solution, aqueous suspension, aqueous dispersion, aqueous mixture, or aqueous emulsion, or an aqueous composition comprising microdroplets.
[0054] In one embodiment of a third aspect of the present invention, the buffer composition comprises Good's buffer, N-substituted aminosulfonic acid (such as BES), N-unsubstituted aminosulfonic acid (such as taurine), aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl (such as imidazole), phenolic acid, amino acid (such as proline), peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or a combination thereof.
[0055] A fourth aspect of the present invention provides an aqueous composition comprising (i) Good's buffer, N-substituted aminosulfonic acid (such as BES), N-unsubstituted aminosulfonic acid (such as taurine), aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl (such as imidazole), phenolic acid, amino acid (such as proline), peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or a combination thereof, and (ii) bicarbonate ions or equivalents thereof, the aqueous composition for use in the treatment, preventive treatment or recovery from an airborne viral infection, or for use in a subject infected with an airborne virus, or a subject exposed to an airborne virus that can cause an airborne viral infection in the subject.
[0056] Typically, the aqueous composition of the fourth aspect of the present invention is also the buffer composition of the third aspect of the present invention.
[0057] One embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) an N-substituted aminosulfonic acid (such as BES) and (ii) a bicarbonate ion or its equivalent.
[0058] One embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) an N-substituted aminosulfonic acid (such as BES) and (ii) a bicarbonate ion.
[0059] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) an N-unsubstituted aminosulfonic acid (such as taurine) and (ii) a bicarbonate ion or an equivalent thereof.
[0060] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) an aminosulfinic acid; and (ii) a bicarbonate ion or an equivalent thereof.
[0061] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) phosphoric acid; and (ii) bicarbonate ions or equivalents thereof.
[0062] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) phosphorous acid; and (ii) bicarbonate ions or equivalents thereof.
[0063] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) a heteroaryl (such as an imidazole); and (ii) a bicarbonate ion or an equivalent thereof.
[0064] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) a phenolic acid; and (ii) a bicarbonate ion or an equivalent thereof.
[0065] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) an amino acid (such as proline) and (ii) a bicarbonate ion or an equivalent thereof.
[0066] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) a peptide or peptide equivalent; and (ii) a bicarbonate ion or equivalent.
[0067] Another embodiment of the first, second, third, or fourth aspect of the present invention provides (i) a polymer buffer; and (ii) an aqueous composition comprising a bicarbonate ion or an equivalent thereof.
[0068] Another embodiment of the first, second, third, or fourth aspect of the present invention provides an aqueous composition comprising (i) urea; and (ii) a bicarbonate ion or an equivalent thereof.
[0069] Another embodiment of the first, second, third, or fourth aspect of the present invention provides (i) an ionic liquid buffer; and (ii) an aqueous composition comprising bicarbonate ions or equivalents thereof.
[0070] In one embodiment of a fourth aspect of the present invention, the aqueous composition is for use in the treatment, preventive treatment, or recovery from an airborne viral infection.
[0071] In another embodiment of a fourth aspect of the present invention, the aqueous composition is intended for use in reducing or preventing (typically reducing) viral replication in subjects infected with an airborne viral infection.
[0072] In a further embodiment of a fourth aspect of the present invention, the aqueous composition is intended for use in reducing or preventing (typically reducing) viral replication in a subject exposed to an airborne virus that can cause an airborne viral infection in the subject.
[0073] In one embodiment of the first, second, third, or fourth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) Good buffer in 1 to 100 mmol / L (preferably 1 to 12 mmol / L), aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 0.1 to 2.5 mmol / L; (iii) 21-35 mmol / L of bicarbonate ions or equivalents; (iv) 2.5 to 6.2 mmol / L of potassium ions; (v) Chloride ions in concentrations of 96-126 mmol / L; and (vi) 100-150 mmol / L of sodium ions.
[0074] In one embodiment of the first, second, third, or fourth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) N-substituted aminosulfonic acid in a concentration of 1 to 12 mmol / L; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 0.1 to 2.5 mmol / L; (iii) 21-35 mmol / L of bicarbonate ions; (iv) 2.5 to 6.2 mmol / L of potassium ions; (v) Chloride ions in concentrations of 96-126 mmol / L; and (vi) 100-150 mmol / L of sodium ions.
[0075] In one embodiment of the first, second, third, or fourth aspect of the present invention, the composition further comprises zinc ions. For example, the composition of the first, second, third, or fourth aspect of the present invention may be a composition (such as an aqueous composition) containing 0.1 to 200 μmol / L of zinc ions. While not intended to be theoretically bound, it is currently believed that zinc ions present in the composition may disrupt ACE2 activity and prevent the binding of wind-borne viruses to host cell membranes. It is also currently believed that zinc ions present in the composition may reduce the replication of viruses, particularly coronaviruses and influenza viruses.
[0076] Zinc ions are antiviral at several levels. In addition to their importance in viral mucociliary removal (Zanin et al, Cell Host Microbe, 2016, vol 19(2), pages 159-168), zinc ions directly suppress cytoplasmic viral replication mediated by viral RNA-dependent RNA polymerase (Te Velthuis et al, PLoS Pathog, 2010, vol 6(11), e1001176). RNA-dependent RNA polymerase is required for the production of subgenomic RNA necessary for the translation and production of the novel viral genome and viral structural proteins. Further steps in the viral life cycle require Mpro (a protease involved in the processing of viral structural proteins during construction). Mpro is also inhibited in the presence of zinc ions (Hsu et al, FEBS Lett, 2004, vol 574(1-3), pages 116-120). It has also been reported that levels of pro-inflammatory cytokines and reactive oxygen species (ROS) (Wessels et al, Nutrients, 2017, vol 9(12), 1286) and inhibition of viral uncoating (Read et al, Adv Nutr, 2019, vol 10(4), pages 696-710) are affected by zinc ion levels.
[0077] In one embodiment of the first, second, third, or fourth aspect of the present invention, the composition further comprises transferrin such as holotransferrin, apotransferrin, or monoferrictransferrin. For example, the composition of the first, second, third, or fourth aspect of the present invention may be a composition (such as an aqueous composition) containing 0.1 to 100 μmol / L of transferrin.
[0078] In one embodiment of the first, second, third, or fourth aspect of the present invention, the composition is Fe 2+ Or Fe 3+ The composition further contains iron ions such as those listed above. For example, a composition according to the first, second, third, or fourth embodiment of the present invention may be a composition (such as an aqueous composition) containing 0.1 to 100 μmol / L of iron ions.
[0079] In one embodiment of the first, second, third, or fourth aspect of the present invention, the composition further comprises transferrin and iron ions. For example, the composition of the first, second, third, or fourth aspect of the present invention may be a composition (such as an aqueous composition) containing 1 to 100 μmol / L of transferrin and 1 to 100 μmol / L of iron ions. While not intended to be theoretically bound, it is currently believed that the transferrin and iron ions present in the composition may help regulate the pH of the interstitial fluid, thereby enhancing the effectiveness of the composition.
[0080] A fifth aspect of the present invention provides an aqueous composition comprising (i) Good buffer, N-substituted aminosulfonic acid (such as BES), N-unsubstituted aminosulfonic acid (such as taurine), aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl (such as imidazole), phenolic acid, amino acid (such as proline), peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or a combination thereof, (ii) bicarbonate ions or equivalents thereof, and (iii) zinc ions.
[0081] Typically, the aqueous composition of the fifth aspect of the present invention is also the buffer composition of the third and / or fourth aspect of the present invention.
[0082] One embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) an N-substituted aminosulfonic acid (such as BES), (ii) a bicarbonate ion or its equivalent, and (iii) a zinc ion.
[0083] One embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) an N-substituted aminosulfonic acid (such as BES), (ii) a bicarbonate ion, and (iii) a zinc ion.
[0084] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) an N-unsubstituted aminosulfonic acid (such as taurine), (ii) a bicarbonate ion or its equivalent, and (iii) a zinc ion.
[0085] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) aminosulfinic acid, (ii) bicarbonate ions or equivalents thereof, and (iii) zinc ions.
[0086] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) phosphoric acid, (ii) bicarbonate ions or equivalents thereof, and (iii) zinc ions.
[0087] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) phosphorous acid, (ii) bicarbonate ions or equivalents thereof, and (iii) zinc ions.
[0088] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) a heteroaryl (such as imidazole), (ii) a bicarbonate ion or its equivalent, and (iii) a zinc ion.
[0089] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) a phenolic acid, (ii) a bicarbonate ion or its equivalent, and (iii) a zinc ion.
[0090] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) an amino acid (such as proline), (ii) a bicarbonate ion or its equivalent, and (iii) a zinc ion.
[0091] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) a peptide or peptide equivalent, (ii) a bicarbonate ion or equivalent, and (iii) a zinc ion.
[0092] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) a polymer buffer, (ii) a bicarbonate ion or its equivalent, and (iii) a zinc ion.
[0093] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) urea, (ii) bicarbonate ions or equivalents thereof, and (iii) zinc ions.
[0094] Another embodiment of the first, second, third, fourth, or fifth aspect of the present invention provides an aqueous composition comprising (i) an ionic liquid buffer, (ii) bicarbonate ions or equivalents thereof, and (iii) zinc ions.
[0095] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) Good buffer in 1 to 100 mmol / L (preferably 1 to 12 mmol / L), aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof; (ii) 21-35 mmol / L of bicarbonate ions or their equivalents; and (iii) Zinc ions in a concentration of 0.1 to 200 μmol / L.
[0096] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) N-substituted aminosulfonic acid in a concentration of 1 to 12 mmol / L; (ii) 21-35 mmol / L of bicarbonate ions; and (iii) Zinc ions in a concentration of 0.1 to 200 μmol / L.
[0097] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) Good buffer in 1 to 100 mmol / L (preferably 1 to 12 mmol / L), aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 0.1 to 2.5 mmol / L; (iii) 21-35 mmol / L of bicarbonate ions or equivalents; (iv) 2.5 to 6.2 mmol / L of potassium ions; (v) Chloride ions at 96-126 mmol / L; (vi) 100-150 mmol / L of sodium ions; and (vii) Zinc ions in concentrations of 0.1 to 200 μmol / L.
[0098] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) N-substituted aminosulfonic acid in a concentration of 1 to 12 mmol / L; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 0.1 to 2.5 mmol / L; (iii) 21-35 mmol / L of bicarbonate ions; (iv) 2.5 to 6.2 mmol / L of potassium ions; (v) Chloride ions at 96-126 mmol / L; (vi) 100-150 mmol / L of sodium ions; and (vii) Zinc ions in concentrations of 0.1 to 200 μmol / L.
[0099] A fifth aspect of the present invention also provides an aqueous composition comprising (i) Good buffer, N-substituted aminosulfonic acid (such as BES), N-unsubstituted aminosulfonic acid (such as taurine), aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl (such as imidazole), phenolic acid, amino acid (such as proline), peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or a combination thereof, (ii) bicarbonate ions or equivalents thereof, and (iii) transferrin and / or iron ions.
[0100] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) Good buffer in 1 to 100 mmol / L (preferably 1 to 12 mmol / L), aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof; (ii) Bicarbonate ions or equivalents in concentrations of 21-35 mmol / L; (iii) 1 to 100 μmol / L of transferrin; and (vi) Iron ions in concentrations of 1 to 100 μmol / L.
[0101] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) N-substituted aminosulfonic acid in a concentration of 1 to 12 mmol / L; (ii) 21-35 mmol / L of bicarbonate ions; (iii) 1 to 100 μmol / L of transferrin; and (vi) Iron ions in concentrations of 1 to 100 μmol / L.
[0102] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) Good buffer in 1 to 100 mmol / L (preferably 1 to 12 mmol / L), aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 0.1 to 2.5 mmol / L; (iii) 21-35 mmol / L of bicarbonate ions or equivalents; (iv) 2.5 to 6.2 mmol / L of potassium ions; (v) Chloride ions at 96-126 mmol / L; (vi) 100-150 mmol / L of sodium ions; (vii) Transferrin in 1-100 μmol / L; and (viii) Iron ions in concentrations of 1 to 100 μmol / L.
[0103] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) N-substituted aminosulfonic acid in a concentration of 1 to 12 mmol / L; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 0.1 to 2.5 mmol / L; (iii) 21-35 mmol / L of bicarbonate ions; (iv) 2.5 to 6.2 mmol / L of potassium ions; (v) Chloride ions at 96-126 mmol / L; (vi) 100-150 mmol / L of sodium ions; (vii) Transferrin in 1-100 μmol / L; and (viii) Iron ions in concentrations of 1 to 100 μmol / L.
[0104] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition comprises Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof. These buffers are described in more detail below. The buffers can be used as is or as salts, for example, as sodium or potassium salts. Preferably, the composition comprises Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, ionic liquid buffer, or a combination thereof. Preferably, the composition comprises Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, amino acids, peptides, peptide equivalents, ionic liquid buffer, or a combination thereof. Preferably, the composition further comprises bicarbonate ions or equivalents, preferably bicarbonate ions.
[0105] Good Buffers In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises Good's buffer. In one embodiment, Good's buffer is present at a concentration of 1 to 100 mmol / L, or 1 to 12 mmol / L, or 3 to 8 mmol / L, or about 5 mmol / L.
[0106] In the present invention, all buffers listed in Figure 1 are considered Good buffers. In the present invention, as shown in Figure 1, Good buffers can be classified into N-substituted aminosulfonic acid Good buffers and non-sulfonic acid Good buffers.
[0107] Aminosulfonic acid buffer In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises an aminosulfonic acid. In one embodiment, the aminosulfonic acid is present at a concentration of 1 to 100 mmol / L, or 1 to 12 mmol / L, or 3 to 8 mmol / L, or about 5 mmol / L.
[0108] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises an N-substituted aminosulfonic acid. In one embodiment, the N-substituted aminosulfonic acid is N-substituted aminosulfonic acid Good buffer (such as BES). In one embodiment, the N-substituted aminosulfonic acid is an N-substituted aminoalkyl sulfonic acid, for example, N-substituted amino(C1-C4 alkyl) sulfonic acid (such as BES) or N-substituted amino(C1-C4 hydroxyalkyl) sulfonic acid.
[0109] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises an N-substituted aminosulfonic acid. In one embodiment, the N-substituted aminosulfonic acid is selected from ACES, AMPSO, BES, CABS, CAPS, CAPSO, CHES, DIPSO, HEPBS, HEPES, HEPPS, HEPPSO, MES, MOBS, MOPS, MOPSO, PIPES, POPSO, TABS, TAPS, TAPSO, TES, or a combination thereof. In one embodiment, the N-substituted aminosulfonic acid is selected from BES, TES, HEPES, PIPES, CAPS, or a combination thereof. In one embodiment, the N-substituted aminosulfonic acid is selected from BES, DIPSO, TES, TAPS, TAPSO, TABS, or a combination thereof. In one embodiment, the N-substituted aminosulfonic acid is selected from BES, DIPSO, or a combination thereof. In one embodiment, the N-substituted aminosulfonic acid is BES.
[0110] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises an N-unsubstituted aminosulfonic acid. In one embodiment, the N-unsubstituted aminosulfonic acid is an N-unsubstituted aminoalkyl sulfonic acid, for example, an N-unsubstituted amino(C1-C4 alkyl) sulfonic acid (such as taurine) or an N-unsubstituted amino(C1-C4 hydroxyalkyl) sulfonic acid.
[0111] In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the composition comprises an N-unsubstituted aminosulfonic acid. In one embodiment, the N-unsubstituted aminosulfonic acid is taurine [H2N-CH2CH2-SO3H], 3-aminopropane-1-sulfonic acid [H2N-CH2CH2CH2-SO3H], amino-2-hydroxypropane-1-sulfonic acid [H2N-CH2-CH(OH)-CH2-SO3H], 4-aminobutane-1-sulfonic acid [H2N-CH2CH2CH2CH2-SO3H], or aminobenzenesulfonic acid (including 2-, 3- and 4-aminobenzenesulfonic acid). In one embodiment, the N-unsubstituted aminosulfonic acid is taurine, or taurine bound to hyaluronic acid, or taurine bound to chitosan, or taurine bound to carrageenan. In one embodiment, the N-unsubstituted aminosulfonic acid is taurine.
[0112] In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the aminosulfonic acid has the structure R a R b N-(CR c R d ) m -SO3H (Formula I) or a pharmaceutically acceptable salt thereof, wherein[[ID=I9]] each -R a is independently hydrogen, -R aaa , -CHO, -COR aaa , -CO2R aaa , -SOR aaa , -SONH2, -SONHR aaa , -SON(R<00(0014>)2, -SO2H, -SO2R aaa , -SO2NH2, -SO2NHR aaa , -SO2N(R aaa )2, -SO3H, -SO3R aaa , -CONH2, -CONHR<00OW19>, -CON(R aaa )2, -C(NH)NH2, -C(NH)NHR [[ID=A7]] aaa , -C(NH)N(R<000l)022>)2, -C(NR aaa [[ID=S2]])NHRaaa 、-C(NR aaa )N(R aaa )2、-R aa -R aaa 、-R aa -OR aaa 、-R aa -SR aaa 、-R aa -OH、-R aa -SH、-R aa -CHO、-R aa -COR aaa 、-R aa -CO2H、-R aa -CO2R aaa 、-R aa -OCOR aaa 、-R aa -SOR aaa 、-R aa -SONH2、-R aa -SONHR aaa 、-R aa -SON(R aaa )2、-R aa -SO2H、-R aa -SO2R aaa 、-R aa -SO2NH2、-R aa -SO2NHR aaa 、-R aa -SO2N(R aaa )2、-R aa -SO3H、-R aa -SO3R aaa 、-R aa -NH2、-R aa -NHR aaa 、-R aa -N(R aaa )2、-R aa -CONH2、-R aa -CONHR aaa 、-R aa -CON(R aaa )2、-R aa -C(NH)NH2、-R aa -C(NH)NHR aaa 、-R aa -C(NH)N(R aaa )2、-R aa -C(NR aaa )NHR aaa 、-Raa -C(NR aaa )N(R aaa )2、-R aaaa -(R aa O) p -H、-R aaaa -(R aa O) p -R aaa 、-R aaaa -(R aa O) p -COR aaa 、-R aaaa -(R aa NR x ) p -H、-R aaaa -(R aa NR x ) p -R aaa 、-R aaaa -(R aa NR x ) p -COR aaa 、-R aaaa -(R aa NR x ) p -CONH2、-R aaaa -(R aa NR x ) p -CONHR aaa 、-R aaaa -(R aa NR x ) p -CON(R aaa )2、-R aaaa -(R aa NR x ) p -C(NH)NH2、-R aaaa -(R aa NR x ) p -C(NH)NHR aaa 、-R aaaa -(R aa NR x ) p -C(NH)N(R aaa )2、-R aaaa -(R aa NR x ) p -C(NR aaa )NHR aaa, or -R aaaa -(R aa NR x ) p -C(NR aaa )N(R aaa )2; Each-R aa These are independently C1-C4 alkylenes or C1-C4 haloalkylenes; Each-R aaa Independently, C1-C 30 Alkyl (preferably C1-C) 12 Alkyl or C1-C6 alkyl), C2-C 30 Alkenyl (preferably C2-C) 12 Alkenyl or C2-C6 alkenyl), C2-C 30 Alkinyl (preferably C2-C 12 The group is an alkynyl or C2-C6 alkynyl, C3-C6 cycloalkyl, phenyl, a 4-7 membered heterocyclic group, or a 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH), and oxo(=O), and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; Each-R aaaa - is independent, bonded, -CO-,-CO2-,-CONH-,-CONR x -,-R aa -CO-,-R aa -CO2-,-R aa -CONH-,-R aa -CONR x -,-R aa -O-,-R aa -NH-, or -R aa -NR x -and; -R b is hydrogen, -R bbb , -CHO, -COR bbb , -CO2R bbb , -SOR bbb , -SONH₂, -SONHR bbb , -SON(R bbb )₂, -SO₂H, -SO₂R[[ID=1�]] bbb , -SO₂NH₂, -SO₂NHR bbb , -SO₂N(R bbb )₂, -SO₃H, -SO₃R bbb , -CONH₂, -CONHR bbb , -CON(R bbb [[ID=二十七]] bbb )₂, -C(NH)NH₂, -C(NH)NHR bbb , -C(NH)N(R bbb )₂, -C(NR bbb )NHR bbb , -C(NR bbb )N(R bbb )₂, -R[[ID=四十]] bb -R bbb , -R bb -OR bbb , -R bb -SR bbb , -R bb [[ID=五十三]] bb -OH, -R bb -SH, -R bb -CHO, -R bb -COR bbb , -R bb -CO₂H, -R bb -CO₂R [[ID=六十六]] bb bbb , -R [[ID=六十八]] bbb bb [[ID=六十九]] bb -OCOR bbb , -R bb -SOR bbb , -R bb -SONH₂, -R bb -SONHR bbb , -R bb -SON(R bbb )₂, -R bb -SO₂H, -R bb -SO₂R bbb , -R bb -SO₂NH₂, -R bb -SO₂NHR bbb , -R bb -SO₂N(R bbb )₂, -Rbb -SO3H、-R bb -SO3R bbb 、-R bb -NH2、-R bb -NHR bbb 、-R bb -N(R bbb )2、-R bb -CONH2、-R bb -CONHR bbb 、-R bb -CON(R bbb )2、-R bb -C(NH)NH2、-R bb -C(NH)NHR bbb 、-R bb -C(NH)N(R bbb )2、-R bb -C(NR bbb )NHR bbb 、-R bb -C(NR bbb )N(R bbb )2、-R bbbb -(R bb O) q -H、-R bbbb -(R bb O) q -R bbb 、-R bbbb -(R bb O) q -COR bbb 、-R bbbb -(R bb NR xx ) q -H、-R bbbb -(R bb NR xx ) q -R bbb 、-R bbbb -(R bb NR xx ) q -COR bbb 、-R bbbb -(R bb NR xx ) q -CONH2、-R bbbb -(R bb NR xx ) q -CONHR bbb 、-R bbbb -(Rbb NR xx ) q -CON(R bbb )2, -R bbbb -(R bb NR xx ) q -C(NH)NH2, -R bbbb -(R bb NR xx ) q -C(NH)NHR bbb , -R bbbb -(R bb NR xx ) q -C(NH)N(R bbb )2, -R bbbb -(R bb NR xx ) q -C(NR bbb )NHR bbb , or -R bbbb -(R bb NR xx ) q -C(NR bbb )N(R bbb )2; Each-R bb These are independently C1-C4 alkylenes or C1-C4 haloalkylenes; Each-R bbb Independently, C1-C 30 Alkyl (preferably C1-C) 12 Alkyl or C1-C6 alkyl), C2-C 30 Alkenyl (preferably C2-C) 12 Alkenyl or C2-C6 alkenyl), C2-C 30 Alkinyl (preferably C2-C 12The group is an alkynyl or C2-C6 alkynyl, C3-C6 cycloalkyl, phenyl, a 4-7 membered heterocyclic group, or a 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH), and oxo(=O), and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; -R bbbb - represents bonds, -CO-, -CO2-, -CONH-, -CONR xx -, -R bb -CO-, -R bb -CO2-, -R bb -CONH-, -R bb -CONR xx -, -R bb -O-, -R bb -NH-, or -R bb -NR xx -and; or -R a and -R b Together with the nitrogen atom to which they are bonded, they form a 4- to 7-membered heterocyclic group, which has (i) one or more halo groups and / or (ii)-R a, -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH), and 1, 2, 3, 4 or 5 substituents independently selected from oxo(=O), and / or (iii) C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1- The C4 alkyl group may be optionally substituted with one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, and -OPH(O)(OH); Each-R c These are independently hydrogen, halo, and -R cc -R ccc , -R cc -OR ccc , -R cc -SR ccc , -R cc -OH, -R cc -SH, -R cc -CHO, -R cc -COR ccc , -R cc -CO2H, -R cc -CO2R ccc , -R cc -OCOR ccc , -R cc -SOR ccc , -R cc -SONH2, -R cc -SONHR ccc , -R cc -SON(R ccc )2, -R cc -SO2H, -R cc -SO2R ccc , -R cc -SO2NH2, -R cc -SO2NHR ccc , -R cc -SO2N(R ccc )2, -R cc -SO3H, -R cc -SO3Rccc 、-R cc -NH2、-R cc -NHR ccc 、-R cc -N(R ccc )2、-R cc -CONH2、-R cc -CONHR ccc 、-R cc -CON(R ccc )2、-R cc -C(NH)NH2、-R cc -C(NH)NHR ccc 、-R cc -C(NH)N(R ccc )2、-R cc -C(NR ccc )NHR ccc 、-R cc -C(NR ccc )N(R ccc )2、-R cccc -(R ccccc O) r -H、-R cccc -(R ccccc O) r -R ccc 、-R cccc -(R ccccc O) r -COR ccc 、-R cccc -(R ccccc NR y ) r -H、-R cccc -(R ccccc NR y ) r -R ccc 、-R cccc -(R ccccc NR y ) r -COR ccc 、-R cccc -(R ccccc NR y ) r -CONH 2 、-R cccc -(R ccccc NR y ) r -CONHR ccc 、-R cccc -(R ccccc NR y )r -CON(R ccc )2, -R cccc -(R ccccc NR y ) r -C(NH)NH2, -R cccc -(R ccccc NR y ) r -C(NH)NHR ccc , -R cccc -(R ccccc NR y ) r -C(NH)N(R ccc )2, -R cccc -(R ccccc NR y ) r -C(NR ccc )NHR ccc , or -R cccc -(R ccccc NR y ) r -C(NR ccc )N(R ccc )2; Each-R cc - is independently a bond, C1-C6 alkylene, C2-C6 alkenylene, or -(CH2) n -(C6H4)-(CH2) n - and each of these may optionally be substituted with one or more halo and / or -OH groups, Each-R ccc Independently, C1-C 12 Alkyl (preferably C1-C6 alkyl), C2-C 12 Alkenyl (preferably C2-C6 alkenyl), C2-C 12The group is an alkynyl (preferably a C2-C6 alkynyl), a C3-C6 cycloalkyl, a phenyl, a 4-7 membered heterocyclic group, or a 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH), and oxo (=O), and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; Each-R cccc - is independent of, combines, -CO-, -CO2-, -CONH-, -CONR y -, -R ccccc -CO-, -R ccccc -CO2-, -R ccccc -CONH-, -R ccccc -CONR y -, -R ccccc -O-, -R ccccc -NH-, or -R ccccc -NR y -and; Each-R ccccc These are independently C1-C4 alkylenes or C1-C4 haloalkylenes; and / or -R b and any -R cThese, together with the atoms to which they are bonded, form a 4- to 7-membered heterocyclic group, each of which has one or more halo groups and / or C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), -CO2-(C1-C4 alkyl), -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH)2, and The C1-C4 alkyl, phenyl, or benzyl groups may be optionally substituted with one or more halo groups and / or one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, and -OPH(O)(OH); and / or any two -R c These, together with the carbon atoms to which they are bonded, form a C4-C7 cycloalkyl or 4-7 membered heterocyclic group, each of which has one or more halo groups and / or C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), -CO2-(C1-C4 alkyl), -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH Each C1-C4 alkyl, phenyl, or benzyl group may be optionally substituted with one or more halo groups and / or one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, and -OPH(O)(OH); and / or any -R bonded to the same carbon atom c and any -R dThese, together with the carbon atoms to which they are bonded, form a C=O or C4-C7 cycloalkyl or 4-7 membered heterocyclic group, and the C4-C7 cycloalkyl or 4-7 membered heterocyclic group has one or more halo groups and / or C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), -CO2-(C1-C4 alkyl), -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)( The C1-C4 alkyl, phenyl, or benzyl groups may be optionally substituted with one or more halo groups and / or one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, and -OPH(O)(OH); Any -(CR c R d )- are each -O- and -NR z - is 2 - (CR c R d -O- or -NR to bond directly to the )- group. z - may be substituted, Each-R d These are independently hydrogen, hydroxyl, halo, C1-C6 alkyl, phenyl, or benzyl, and each C1-C6 alkyl, phenyl, or benzyl group may optionally be substituted with one or more halo and / or -OH groups; Each-R x is hydrogen or a C1-C4 alkyl group; Each-R xx is hydrogen or a C1-C4 alkyl group; Each-R y is hydrogen or a C1-C4 alkyl group; Each-R z is hydrogen or C1-C4 alkyl, or -R a and; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; Each n is independently 0, 1, or 2; Each p is 1, 2, 3, 4, 5, or 6; q is 1, 2, 3, 4, 5 or 6; and r is 0, 1, 2, 3, 4, 5, or 6.
[0113] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, aminosulfonic acid is structure R a R b N-(CR c R d ) m -SO3H (formula I) or having a pharmaceutically acceptable salt thereof, in the formula, -R a These are, independently, hydrogen, -R aaa -CHO, -COR aaa , -CO2R aaa -SOR aaa -SONH2, -SONHR aaa -SON(R aaa )2, -SO2H, -SO2R aaa -SO2NH2, -SO2NHR aaa , -SO2N(R aaa )2, -SO3H, -SO3R aaa -CONH2, -CONHR aaa , -CON(R aaa )2, -C(NH)NH2, -C(NH)NHR aaa ,-C(NH)N(R aaa )2, -C(NR aaa )NHR aaa -C(NR aaa )N(R aaa )2, -R aa -R aaa , -R aa -OR aaa , -R aa -SR aaa , -R aa -OH, -R aa -SH, -R aa -CHO, -R aa -COR aaa , -R aa-CO2H, -R aa -CO2R aaa , -R aa -OCOR aaa , -R aa -SOR aaa , -R aa -SONH2, -R aa -SONHR aaa , -R aa -SON(R aaa )2, -R aa -SO2H, -R aa -SO2R aaa , -R aa -SO2NH2, -R aa -SO2NHR aaa , -R aa -SO2N(R aaa )2, -R aa -SO3H, -R aa -SO3R aaa , -R aa -NH2, -R aa -NHR aaa , -R aa -N(R aaa )2, -R aa -CONH2, -R aa -CON editing aaa , -R aa -CON(R aaa )2, -R aa -C(NH)NH2, -R aa -C(NH)NHR aaa , -R aa -C(NH)N(R aaa )2, -R aa -C(NR aaa )NHR aaa , or -R aa -C(NR aaa )N(R aaa )2; -R aa These are independently C1-C4 alkylenes or C1-C4 haloalkylenes; Each-R aaa Independently, C1-C 30 Alkyl (preferably C1-C) 12 Alkyl or C1-C6 alkyl), C2-C 30 Alkenyl (preferably C2-C)12 Alkenyl or C2-C6 alkenyl), C2-C 30 Alkinyl (preferably C2-C 12 The group is an alkynyl or C2-C6 alkynyl, C3-C6 cycloalkyl, phenyl, a 4-7 membered heterocyclic group, or a 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH), and oxo(=O), and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; -R b is hydrogen, -R bbb -CHO, -COR bbb , -CO2R bbb -SOR bbb -SONH2, -SONHR bbb -SON(R bbb )2, -SO2H, -SO2R bbb -SO2NH2, -SO2NHR bbb , -SO2N(R bbb )2, -SO3H, -SO3R bbb -CONH2, -CONHR bbb , -CON(R bbb )2, -C(NH)NH2, -C(NH)NHR bbb ,-C(NH)N(R bbb )2, -C(NR bbb )NHR bbb -C(NR bbb )N(R bbb )2, -R bb -R bbb , -R bb -OR bbb , -R bb -SR bbb , -R bb-OH, -R bb -SH, -R bb -CHO, -R bb -COR bbb , -R bb -CO2H, -R bb -CO2R bbb , -R bb -OCOR bbb , -R bb -SOR bbb , -R bb -SONH2, -R bb -SONHR bbb , -R bb -SON(R bbb )2, -R bb -SO2H, -R bb -SO2R bbb , -R bb -SO2NH2, -R bb -SO2NHR bbb , -R bb -SO2N(R bbb )2, -R bb -SO3H, -R bb -SO3R bbb , -R bb -NH2, -R bb -NHR bbb , -R bb -N(R bbb )2, -R bb -CONH2, -R bb -CON editing bbb , -R bb -CON(R bbb )2, -R bb -C(NH)NH2, -R bb -C(NH)NHR bbb , -R bb -C(NH)N(R bbb )2, -R bb -C(NR bbb )NHR bbb , or -R bb -C(NR bbb )N(R bbb )2; -R bb These are independently C1-C4 alkylenes or C1-C4 haloalkylenes; Each-R bbb Independently, C1-C30 Alkyl (preferably C1-C) 12 Alkyl or C1-C6 alkyl), C2-C 30 Alkenyl (preferably C2-C) 12 Alkenyl or C2-C6 alkenyl), C2-C 30 Alkinyl (preferably C2-C 12 The group is an alkynyl or C2-C6 alkynyl, C3-C6 cycloalkyl, phenyl, a 4-7 membered heterocyclic group, or a 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH), and oxo(=O), and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; or -R a and -R bThese, together with the nitrogen atoms to which they are bonded, form a 4- to 7-membered heterocyclic group, which consists of (i) one or more halo groups, and / or (ii) one, two, three, four or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH), and oxo(=O), and / or (iii) C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl ), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl) may optionally be substituted with 1, 2, 3, 4, or 5 substituents independently selected from each of these, each of which may optionally be substituted with 1 or more halo groups and / or 1, 2, 3, 4, or 5 substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, and -OPH(O)(OH); Each-R c These are independently hydrogen, halo, and -R cc -R ccc , -R cc -OR ccc , -R cc -SR ccc , -R cc -OH, -R cc -SH, -R cc -CHO, -R cc -COR ccc , -R cc -CO2H, -R cc -CO2R ccc , -R cc -OCOR ccc , -R cc -SOR ccc , -R cc -SONH2, -R cc -SONHR ccc , -R cc -SON(R ccc )2, -R cc -SO2H, -R cc -SO2R ccc , -R cc -SO2NH2, -R cc -SO2NHR ccc , -R cc-SO2N(R ccc )2, -R cc -SO3H, -R cc -SO3R ccc , -R cc -NH2, -R cc -NHR ccc , -R cc -N(R ccc )2, -R cc -CONH2, -R cc -CON editing ccc , -R cc -CON(R ccc )2, -R cc -C(NH)NH2, -R cc -C(NH)NHR ccc , -R cc -C(NH)N(R ccc )2, -R cc -C(NR ccc )NHR ccc , or -R cc -C(NR ccc )N(R ccc )2; Each-R cc - is independently a bond, C1-C6 alkylene, C2-C6 alkenylene, or -(CH2) n -(C6H4)-(CH2) n - and each of these may optionally be substituted with one or more halo and / or -OH groups, Each-R ccc Independently, C1-C 12 Alkyl (preferably C1-C6 alkyl), C2-C 12 Alkenyl (preferably C2-C6 alkenyl), C2-C 12The group is an alkynyl (preferably a C2-C6 alkynyl), a C3-C6 cycloalkyl, a phenyl, a 4-7 membered heterocyclic group, or a 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH), and oxo (=O), and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; and / or -R b and any -R c These, together with the atoms to which they are bonded, form a 4- to 7-membered heterocyclic group, each of which has one or more halo groups and / or C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), -CO2-(C1-C4 alkyl), -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH(O)(OH)2, and The C1-C4 alkyl, phenyl, or benzyl groups may be optionally substituted with one or more halo groups and / or one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, and -OPH(O)(OH); and / or any two -R cThese, together with the carbon atoms to which they are bonded, form a C4-C7 cycloalkyl or 4-7 membered heterocyclic group, each of which has one or more halo groups and / or C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), -CO2-(C1-C4 alkyl), -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, -OPH Each C1-C4 alkyl, phenyl, or benzyl group may be optionally substituted with one or more halo groups and / or one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, and -OPH(O)(OH); and / or any -R bonded to the same carbon atom c and any -R d These, together with the carbon atoms to which they are bonded, form a C=O or C4-C7 cycloalkyl or 4-7 membered heterocyclic group, and the C4-C7 cycloalkyl or 4-7 membered heterocyclic group has one or more halo groups and / or C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), -CO2-(C1-C4 alkyl), -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)( The C1-C4 alkyl, phenyl, or benzyl groups may be optionally substituted with one or more halo groups and / or one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, -CONH2, -OP(O)(OH)2, and -OPH(O)(OH); Any -(CR c R d )- are each -O- and -NR z- is 2 - (CR c R d -O- or -NR to bond directly to the )- group. z - may be substituted, Each-R d These are independently hydrogen, hydroxyl, halo, C1-C6 alkyl, phenyl, or benzyl, and each C1-C6 alkyl, phenyl, or benzyl group may optionally be substituted with one or more halo and / or -OH groups; Each-R z is hydrogen or a C1-C4 alkyl group; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and Each n is independently 0, 1, or 2.
[0114] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, aminosulfonic acid is structure R a R b N-(CR c R d ) m -SO3H (formula I) or having a pharmaceutically acceptable salt thereof, in the formula, -R a These are, independently, hydrogen, -R aaa -CHO, -COR aaa , -CO2R aaa , -R aa -R aaa , -R aa -OR aaa , -R aa -SR aaa , -R aa -OH, -R aa -SH, -R aa -CHO, -R aa -COR aaa , -R aa -CO2H, -R aa -CO2R aaa , -R aa -OCOR aaa , -R aa -NH2, -R aa -NHR aaa , or -Raa -N(R aaa )2; -R aa These are independently C1-C4 alkylenes or C1-C4 haloalkylenes; Each-R aaa Independently, C1-C 12 Alkyl (preferably C1-C6 alkyl), C2-C 12 Alkenyl (preferably C2-C6 alkenyl), C2-C 12 The alkynyl (preferably C2-C6 alkynyl), C3-C6 cycloalkyl, phenyl, 4-7 membered heterocyclic group, or 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, and -CONH2, and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; -R b is hydrogen, -R bbb -CHO, -COR bbb , -CO2R bbb , -R bb -R bbb , -R bb -OR bbb , -R bb -SR bbb , -R bb -OH, -R bb -SH, -R bb -CHO, -R bb -COR bbb , -R bb -CO2H, -R bb -CO2R bbb , -R bb -OCOR bbb , -R bb -NH2, -R bb -NHR bbb , or -Rbb -N(R bbb )2; -R bb These are independently C1-C4 alkylenes or C1-C4 haloalkylenes; Each-R bbb Independently, C1-C 12 Alkyl (preferably C1-C6 alkyl), C2-C 12 Alkenyl (preferably C2-C6 alkenyl), C2-C 12 The alkynyl (preferably C2-C6 alkynyl), C3-C6 cycloalkyl, phenyl, 4-7 membered heterocyclic group, or 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, and -CONH2, and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; or -R a and -R b Together with the nitrogen atom to which they are bonded, they form a 4- to 7-membered heterocyclic group, which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, and -CONH2, and / or (iii) one, two, three, four or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo groups and / or one, two, three, four or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, and -CONH2; Each-R c These are independently hydrogen, halo, and -R cc -R ccc , -R cc -OR ccc , -R cc -SR ccc , -R cc -OH, -R cc -SH, -R cc -CHO, -R cc -COR ccc , -R cc -CO2H, -R cc -CO2R ccc , -R cc -OCOR ccc , -R cc -NH2, -R cc -NHR ccc , or -R cc -N(R ccc )2; Each-R cc - is independently a bond, a C1-C6 alkylene, or a C2-C6 alkenylene, each of which may be optionally substituted with one or more halo and / or -OH groups. Each-R ccc Independently, C1-C 12 Alkyl (preferably C1-C6 alkyl), C2-C 12 Alkenyl (preferably C2-C6 alkenyl), C2-C 12 The alkynyl (preferably C2-C6 alkynyl), C3-C6 cycloalkyl, phenyl, 4-7 membered heterocyclic group, or 5-6 membered heteroaryl group, each of which may be optionally substituted with (i) one or more halo groups and / or (ii) one, two, three, four, or five substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, and -CONH2, and / or (iii) one, two, three, four, or five substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), and -CO2-(C1-C4 alkyl), each of which may be optionally substituted with one or more halo and / or -OH groups; and / or any two -R c Together with the carbon atoms to which they are bonded, they form a C4-C7 cycloalkyl or 4-7 membered heterocyclic group, each of which may be optionally substituted with one or more halo groups and / or 1, 2, 3, 4, or 5 substituents independently selected from C1-C4 alkyl, phenyl, benzyl, -O-(C1-C4 alkyl), -O-CO-(C1-C4 alkyl), -CO2-(C1-C4 alkyl), -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, and -CONH2, and each C1-C4 alkyl, phenyl, or benzyl group may be optionally substituted with one or more halo groups and / or 1, 2, 3, 4, or 5 substituents independently selected from -OH, -SH, -NH2, -CN, -CO2H, -SO2H, -SO3H, and -CONH2; Any -(CR c R d )- are each -O- and -NR z - is 2 - (CR c R d -O- or -NR to bond directly to the )- group. z - may be substituted, Each-R d These are independently hydrogen, hydroxyl, halo, C1-C6 alkyl, phenyl, or benzyl, and each C1-C6 alkyl, phenyl, or benzyl group may optionally be substituted with one or more halo and / or -OH groups; Each-R z is hydrogen or C1-C4 alkyl; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.
[0115] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, aminosulfonic acid is structure R a R b N-(CR c R d ) m -SO3H (formula I) It has, in the formula, -Ra is hydrogen or a C1-C4 alkyl, C3-C6 cycloalkyl, 4-7 heterocyclic group or 5-6 membered heteroaryl group, and the C1-C4 alkyl, C3-C6 cycloalkyl, heterocyclic or heteroaryl group may be optionally substituted with one or more fluoro groups and / or one, two or three substituents independently selected from C1-C4 alkyl, hydroxy, SO3H and CONH2; -R b is hydrogen or a C1-C4 alkyl, C3-C6 cycloalkyl, 4-7 heterocyclic group or 5-6 membered heteroaryl group, and the C1-C4 alkyl, C3-C6 cycloalkyl, heterocyclic or heteroaryl group may be optionally substituted with one or more fluoro groups and / or one, two or three substituents independently selected from C1-C4 alkyl, hydroxy, SO3H and CONH2; or -R a and -R b Together with the nitrogen atom to which they are bonded, they form a 4- to 7-membered heterocyclic group or a 5- to 6-membered heteroaryl group, the heterocyclic or heteroaryl group may optionally be substituted with one or more fluoro groups and / or one, two, or three substituents independently selected from C1-C4 alkyl, hydroxy, SO3H, and CONH2, and each C1-C4 alkyl group may optionally be substituted with one or more fluoro groups and / or one, two, or three substituents independently selected from hydroxy, SO3H, and CONH2; Each-R c The -R is independently selected from hydrogen, hydroxyl, and fluoro, and / or any two -R c Together with the carbon atoms to which they are bonded, they form a C5-C6 cycloalkyl or 4-7 membered heterocyclic group, and the C5-C6 cycloalkyl or heterocyclic group may be optionally substituted with one or more fluoro groups and / or one, two, or three substituents independently selected from C1-C4 alkyl, hydroxy, SO3H, and CONH2; Each R d is independently selected from hydrogen and fluoro; and m is 1, 2, 3, or 4.
[0116] -R a and -R b If both are hydrogen atoms, the aminosulfonic acid of formula (I) is an N-unsubstituted aminosulfonic acid. -R a and -R b If one or both of the atoms are not hydrogen, the aminosulfonic acid of formula (I) is an N-substituted aminosulfonic acid.
[0117] In one embodiment, -R a and -R b Together with the nitrogen atom to which they are bonded, they form a morpholinyl or piperazinyl group, and the piperazinyl group may be optionally substituted with a C1-C4 alkyl group which may be optionally substituted with one, two, or three substituents independently selected from hydroxyl and SO3H.
[0118] In another embodiment, -R a H is H, and -R b It is cyclohexyl.
[0119] In another embodiment, -R a is a C1-C4 alkyl group substituted with H or 1, 2, or 3 hydroxyl groups, and -R b It is a C1-C4 alkyl group substituted with one, two, or three substituents independently selected from hydroxyl and CONH2.
[0120] In another embodiment, -R a and -R b It is hydrogen.
[0121] In one embodiment, -R c It is hydrogen or hydroxyl.
[0122] In one embodiment, -R d It is hydrogen.
[0123] In one embodiment, m is 2, 3, 4, 5, 6, 7, 8, 9, or 10. In another embodiment, m is 2, 3, 4, 5, 6, 7, or 8. In yet another embodiment, m is 2, 3, 4, 5, or 6. In yet another embodiment, m is 2, 3, or 4. In yet another embodiment, m is 2 or 3.
[0124] In one embodiment, the aminosulfonic acid of formula (I) does not contain either an -OP(O)(OH)2 or an -OPH(O)(OH) group.
[0125] In one embodiment, the aminosulfonic acid of formula (I) has a molecular weight of 4,000 Da or less, 2,000 Da or less, 1,000 Da or less, or 500 Da or less.
[0126] Suitable aminosulfonic acids are also taught in Grygorenko et al. (Tetrahedron, 2018, vol 74, pages 1355-1421) and WO2015 / 073648. Both of these documents are incorporated herein by reference in their entirety.
[0127] Aminosulfinic acid buffer In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises aminosulfinic acid. In one embodiment, the aminosulfinic acid is present at a concentration of 1 to 100 mmol / L, or 1 to 12 mmol / L, or 3 to 8 mmol / L, or about 5 mmol / L.
[0128] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the aminosulfinic acid is an aminoalkylsulfinic acid, for example, an amino(C1-C4 alkyl)sulfinic acid or an amino(C1-C4 hydroxyalkyl)sulfinic acid.
[0129] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the aminosulfinic acid includes an N-substituted aminosulfinic acid. In one embodiment, the N-substituted aminosulfinic acid is (HOCH2CH2)2N-CH2CH2-SO2H.
[0130] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the aminosulfinic acid includes N-unsubstituted aminosulfinic acid. In one embodiment, the N-unsubstituted aminosulfinic acid is 2-aminoethane-1-sulfinic acid [H2N-CH2CH2-SO2H], 3-aminopropane-1-sulfinic acid [H2N-CH2CH2CH2-SO2H], 3-amino-2-hydroxypropane-1-sulfinic acid [H2N-CH2-CH(OH)-CH2-SO2H], 4-aminobutane-1-sulfinic acid [H2N-CH2CH2CH2CH2-SO2H], or aminobenzenesulfinic acid (including 2-, 3-, and 4-aminobenzenesulfinic acid). In one embodiment, the N-unsubstituted aminosulfinic acid is 2-aminoethane-1-sulfinic acid, or 2-aminoethane-1-sulfinic acid bonded to hyaluronic acid, or 2-aminoethane-1-sulfinic acid bonded to chitosan, or 2-aminoethane-1-sulfinic acid bonded to carrageenan. In one embodiment, the N-unsubstituted aminosulfinic acid is 2-aminoethane-1-sulfinic acid.
[0131] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, aminosulfinic acid is structure R a R b N-(CR c R d ) m -SO2H (formula II) It has -R a , -R b , -R c , -R d and m are as defined for equation (I) above. To avoid misunderstanding, the above equation (I) is summarized as -R a , -R b , -R c, -R d And the embodiments of m are -R of formula (II). a , -R b , -R c , -R d Note that this also applies equally to m.
[0132] In one embodiment, the aminosulfinic acid of formula (II) does not contain either an -OP(O)(OH)2 or an -OPH(O)(OH) group.
[0133] In one embodiment, the aminosulfinic acid of formula (II) has a molecular weight of 4,000 Da or less, 2,000 Da or less, 1,000 Da or less, or 500 Da or less.
[0134] Aminosulfinic acid has a chiral sulfur atom. This invention encompasses racemic mixtures of aminosulfinic acid, as well as concentrated enantiomers and pure aminosulfinic acid as enantiomers.
[0135] While not bound by theory, it is currently believed that aminosulfinic acids can be oxidized to their corresponding aminosulfonic acids in vivo.
[0136] Phosphate buffer In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition contains phosphoric acid. In one embodiment, phosphoric acid is present at a concentration of 1 to 500 mmol / L, or 1 to 200 mmol / L, or 1 to 100 mmol / L, or 1 to 50 mmol / L, or 1 to 12 mmol / L.
[0137] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, phosphoric acid is inorganic phosphoric acid, such as sodium phosphate (NaH2PO4, or Na2HPO4, etc.), potassium phosphate (KH2PO4, or K2HPO4, etc.), calcium phosphate (Ca3(PO4)2, CaHPO4, Ca(H2PO4)2, or Ca2P2O7, etc.), magnesium phosphate (Mg3(PO4)2, MgHPO4, or Mg(H2PO4)2, etc.), zinc phosphate (Zn3(PO4)2, ZnHPO4, or Zn(H2PO4)2, etc.), iron phosphate (Fe3(PO4)2, FeHPO4, Fe(H2PO4)2, or FePO4, etc.), or a combination thereof. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the phosphoric acid is an inorganic phosphoric acid selected from NaH2PO4, Na2HPO4, KH2PO4, K2HPO4, or a combination thereof.
[0138] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the phosphoric acid is an organophosphoric acid, such as an alkyl dihydrogen phosphate (e.g., methyl dihydrogen phosphate, ethyl dihydrogen phosphate, propyl dihydrogen phosphate, or butyl dihydrogen phosphate).
[0139] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the phosphoric acid is an organophosphoric acid, such as dialkyl hydrogen phosphate (e.g., dimethyl hydrogen phosphate, diethyl hydrogen phosphate, dipropyl hydrogen phosphate, or dibutyl hydrogen phosphate).
[0140] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the phosphoric acid is an organophosphoric acid, such as tris(perfluoroalkyl)trifluorophosphate (tris(pentafluoroethyl)trifluorophosphate, etc.).
[0141] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, phosphoric acid is an organic phosphoric acid, such as aminophosphoric acid. In one embodiment, aminophosphoric acid is amino(C1-C4 alkyl)phosphoric acid or amino(C1-C4 hydroxyalkyl)phosphoric acid.
[0142] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, aminophosphate is structure R a R b N-(CR c R d ) m -OP(O)(OH)2 (Equation III) It has -R a , -R b , -R c , -R d and m are as defined for equation (I) above. To avoid misunderstanding, the above equation (I) is summarized as -R a , -R b , -R c , -R d And the embodiments of m are -R of formula (III). a , -R b , -R c , -R d Note that this also applies equally to m.
[0143] In one embodiment, the aminophosphate of formula (III) has a molecular weight of 4,000 Da or less, 2,000 Da or less, 1,000 Da or less, or 500 Da or less.
[0144] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition does not contain inorganic phosphoric acid.
[0145] phosphite buffer In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition contains phosphorous acid. In one embodiment, the phosphorous acid is present at a concentration of 1 to 500 mmol / L, or 1 to 200 mmol / L, or 1 to 100 mmol / L, or 1 to 50 mmol / L, or 1 to 12 mmol / L.
[0146] In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the phosphorous acid is an inorganic phosphorous acid, for example, sodium phosphite (such as NaH2PO3 or Na2HPO3), potassium phosphite (such as KH2PO3 or K2HPO3), calcium phosphite (such as Ca3(PO3)2, CaHPO3 or Ca(H2PO3)2), magnesium phosphite (such as Mg3(PO3)2, MgHPO3 or Mg(H2PO3)2), zinc phosphite (such as Zn3(PO3)2, ZnHPO3 or Zn(H2PO3)2), iron phosphite (such as Fe3(PO3)2, FeHPO3, Fe(H2PO3)2 or FePO3), or a combination thereof.
[0147] In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the phosphorous acid is an organic phosphorous acid, for example, alkyl dihydrogen phosphite (such as methyl dihydrogen phosphite or ethyl dihydrogen phosphite).
[0148] In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the phosphorous acid is an organic phosphorous acid, for example, dialkyl hydrogen phosphite (such as dimethyl hydrogen phosphite or diethyl hydrogen phosphite).
[0149] In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the phosphorous acid is an organic phosphorous acid, for example, amino phosphorous acid and the like. In one embodiment, the amino phosphorous acid is amino (C1-C4 alkyl) phosphorous acid or amino (C1-C4 hydroxyalkyl) phosphorous acid.
[0150] In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the amino phosphorous acid has the structure R a R b N-(CR c R d )> m -OPH(O)(OH) (Formula IV) and -R a 、-R b 、-R c 、-R dand m are as defined for the above formula (I). For the sake of avoiding misunderstanding, -R outlined for the above formula (I) is noted a , -R b , -R c , -R d Embodiments of and m are equally applicable to -R of formula (IV) a , -R b , -R c , -R d and note that it also equally applies to m.
[0151] In one embodiment, the aminophosphonic acid of formula (IV) has a molecular weight of 4,000 Da or less, 2,000 Da or less, or 1,000 Da or less, or the molecular weight of 500 Da or less.
[0152] In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the composition does not contain inorganic phosphonic acid. In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the composition does not contain phosphonic acid.
[0153] Heteroaryl buffer In one embodiment of the first, second, third, fourth or fifth aspect of the present invention, the composition contains a 5- or 6-membered heteroaryl containing 1, 2 or 3 nitrogen atoms such as pyridine, pyridazine, pyrimidine, pyrazine, triazine, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole or thiadiazole, each of which may be optionally substituted with, for example, 1, 2 or 3 C1-C6 alkyl groups. In one embodiment, the 5- or 6-membered heteroaryl containing 1, 2 or 3 nitrogen atoms is present at a concentration of 1 to 100 mmol / L, or a concentration of 1 to 12 mmol / L, or a concentration of 3 to 8 mmol / L, or a concentration of about 5 mmol / L.
[0154] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises imidazole. In one embodiment, the imidazole is present at a concentration of 1 to 100 mmol / L, or 1 to 12 mmol / L, or 3 to 8 mmol / L, or about 5 mmol / L.
[0155] Phenolic acid buffer In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises a phenolic acid, such as hydroxybenzoic acid or hydroxycinnamic acid. In one embodiment, the phenolic acid is present at a concentration of 1 to 100 mmol / L, or 1 to 12 mmol / L, or 3 to 8 mmol / L, or about 5 mmol / L.
[0156] Amino acid, peptide, and peptide equivalent buffer solutions In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises an amino acid, a peptide, or a peptide equivalent. In one embodiment, the amino acid, peptide, or peptide equivalent is present at a concentration of 1 to 100 mmol / L, or 1 to 12 mmol / L, or 3 to 8 mmol / L, or about 5 mmol / L.
[0157] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the amino acid is an α-amino acid. In one embodiment, the α-amino acid is a natural α-amino acid. In one embodiment, the α-amino acid is cysteine, glycine, proline, hydroxyproline, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, tryptophan, arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, or citrulline. In one embodiment, the α-amino acid is proline, hydroxyproline, cysteine, leucine, histidine, or citrulline.
[0158] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the amino acid is a β-amino acid. In one embodiment, the β-amino acid is 3-aminopropionic acid or 2-aminobenzoic acid (anthranilic acid).
[0159] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the amino acid is a γ- or δ-amino acid, for example, 4-aminobutanoic acid or 5-aminopentanoic acid.
[0160] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the peptide is a dipeptide. In one embodiment, the dipeptide contains or consists of α-, β-, γ-, or δ-amino acids. In one embodiment, the dipeptide contains or consists of α-, β-, or γ-amino acids. In one embodiment, the dipeptide consists of α-, β-, or γ-amino acids. In one embodiment, the dipeptide consists of α- or β-amino acids. In one embodiment, the dipeptide consists of α-amino acids. In one embodiment, the dipeptide is amphoteric. In one embodiment, the dipeptide is glycylglycine, alanylglutamine, β-alanylhistidine (carnosine), β-alanyl 3-methylhistidine (anserine), glycylglutamine, or N-substituted derivatives thereof (such as N-acetylated derivatives).
[0161] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the peptide is a tripeptide. In one embodiment, the tripeptide contains or consists of α-, β-, γ-, or δ-amino acids. In one embodiment, the tripeptide contains or consists of α-, β-, or γ-amino acids. In one embodiment, the tripeptide consists of α-, β-, or γ-amino acids. In one embodiment, the tripeptide consists of α- or β-amino acids. In one embodiment, the tripeptide consists of α-amino acids. In one embodiment, the tripeptide is amphoteric. In one embodiment, the tripeptide is glutathione, lysine-proline-valine (KPV), or N-substituted derivatives thereof (such as N-acetylated derivatives).
[0162] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the peptide equivalent is a dipeptide equivalent. In one embodiment, the dipeptide equivalent comprises or consists of α-amino acids, β-amino acids, γ-amino acids, aminosulfonic acids and / or aminosulfinic acids. In one embodiment, the dipeptide equivalent consists of α-amino acids, β-amino acids, γ-amino acids, aminosulfonic acids and / or aminosulfinic acids. In one embodiment, the dipeptide equivalent is amphoteric. In one embodiment, the dipeptide equivalent is tauryltaurine (taurine dimer), glutamyltaurine, aspartyltaurine, ceryltaurine, or N-substituted derivatives thereof (such as N-acetylated derivatives). In one embodiment, the dipeptide equivalent comprises taurine and α-, β-, γ-amino acids, for example, the dipeptide equivalent is glutamyltaurine, aspartyltaurine, ceryltaurine, or N-substituted derivatives thereof (such as N-acetylated derivatives).
[0163] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the peptide equivalent is a tripeptide equivalent. In one embodiment, the tripeptide equivalent comprises or consists of α-amino acids, β-amino acids, γ-amino acids, aminosulfonic acids and / or aminosulfinic acids. In one embodiment, the tripeptide equivalent consists of α-amino acids, β-amino acids, γ-amino acids, aminosulfonic acids and / or aminosulfinic acids. In one embodiment, the tripeptide equivalent is amphoteric. In one embodiment, the tripeptide equivalent is a taurine trimer or its N-substituted derivative (such as an N-acetylated derivative).
[0164] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the peptide equivalent is a di, tri, or tetrapeptide equivalent comprising or consisting of an α-amino acid and taurine.
[0165] Suitable peptide equivalents have also been taught by Grygorenko et al. (Tetrahedron, 2018, vol 74, pages 1355-1421), Vertesaljai et al. (J Org Chem, 2014, vol 79(6), pages 2688-2693), and Ienaga et al. (Chem Pharm Bull, 1988, vol 36(1), pages 70-77). Both of these publications are incorporated herein by reference in their entirety.
[0166] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises a fluorinated amino acid, a fluorinated peptide, or a fluorinated peptide equivalent.
[0167] Polymer buffer In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises a polymer buffer.
[0168] In one embodiment, the polymer buffer is a polymer that is a buffer itself, such as chitosan, polycations (such as polyethyleneimine or polylysine), hemoglobin, ovalbumin, or derivatives thereof.
[0169] In another embodiment, the polymer buffer is a binding buffer, i.e., a polymer modified with buffering groups such as N-substituted aminosulfonic acid (e.g., BES), N-unsubstituted aminosulfonic acid (e.g., taurine), aminosulfinic acid, phosphoric acid, phosphite, heteroaryl (e.g., imidazole), phenolic acid, amino acid (e.g., proline), peptide, peptide equivalent, or urea-modified dendrimers, peptides, hyaluronic acid, chitosan, or carrageenan.
[0170] In one embodiment, the buffering groups (or more) of the polymer buffer are present at concentrations of 1 to 500 mmol / L, 1 to 200 mmol / L, 1 to 100 mmol / L, 1 to 50 mmol / L, or 1 to 12 mmol / L.
[0171] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, an N-substituted aminosulfonic acid (such as BES), an N-unsubstituted aminosulfonic acid (such as taurine), an aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl (such as imidazole), a phenolic acid, an amino acid (such as proline), a peptide, a peptide equivalent, or urea is bound to a polymer such as hyaluronic acid or chitosan. Typically, in such embodiments, the polymer to which the N-substituted aminosulfonic acid, N-unsubstituted aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, a phenolic acid, an amino acid, a peptide, a peptide equivalent, or urea is bound is dissolved or suspended in water. In one embodiment, the polymer is water-soluble chitosan. In one embodiment, the polymer is chitosan bound to urocanic acid. In one embodiment, the polymer is water-soluble chitosan bound to urocanic acid.
[0172] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition comprises a carrageenan derivative or analog as a buffer. Carrageenan and its derivatives and analogs, as well as preparations thereof, are disclosed, for example, by Yamada et al., Carbohydrate Polymers, 1997, vol 32, pages 51-55. This document is incorporated herein by reference in its entirety.
[0173] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises a dendrimer as a buffer.
[0174] Dendrimers are highly ordered and highly branched polymers. A dendrimer is defined by three components: a central core, an internal dendritic structure (branching), and an outer surface with functional surface groups. Typically, dendrimers are symmetrical around the core and often take on a spherical three-dimensional form. Their branching structure generates numerous surface sites relative to the total molecular volume. [ka]
[0175] Poly(amideamines), or PAMAMs, are a group of dendrimers made from repeating branched subunits of amide and amine functional groups. Like other dendrimers, PAMAMs have an overall spherical shape and an inner molecular structure consisting of dendritic branching with exponentially increasing branching points, each of which is an outer "layer" or generation.
[0176] PAMAM can be synthesized by using ethylenediamine as a core initiator and alternately carrying out the following two reactions to grow outwards. 1. Michael addition to the methyl acrylate on the amino group terminal surface (which results in the formation of an ester terminal outer layer), and 2. By bonding with ethylenediamine, a novel amino group-terminated surface is obtained. [ka]
[0177] Conventional PAMAM can be converted into a buffer by, for example, hydrolyzing the surface ester to the corresponding carboxylic acid (see (a) in the scheme below), or by end-capping the surface amine with an acid such as a carboxylic acid (see (b) in the scheme below) or sulfonic acid (see (c) and (d) in the scheme below). The resulting PAMAM dendrimer, having an amine-rich basic core and an acid-terminated surface, is an effective buffer. scheme [ka]
[0178] For example, suitable dendrimers that can be surface-modified with the aforementioned carboxylic acids or sulfonic acids are also taught by Dykes, J Chem Technol Biotechnol, 2001, vol 76, pages 903-918; Abbasi et al, Nanoscale Research Letters, 2014, vol 9, article 247; Baig et al, IJAPBC, 2015, vol 4(1), pages 44-59; Shahi et al, Int J Pharm Sci Rev Res, 2015, vol 33(1), pages 187-198; and Gupta et al, J Appl Pharm Sci, 2015, vol 5(3), pages 117-122. All of these publications are incorporated herein by reference in their entirety.
[0179] urea buffer In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises urea R2N-CO-NR2, where each R is independently selected from hydrogen or C1-C6 alkyl. In one embodiment, the urea is present at a concentration of 1 to 100 mmol / L, or 1 to 12 mmol / L, or 3 to 8 mmol / L, or about 5 mmol / L.
[0180] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises urea (H2N-CO-NH2). In one embodiment, the urea is present at a concentration of 1 to 100 mmol / L, or 1 to 12 mmol / L, or 3 to 8 mmol / L, or about 5 mmol / L.
[0181] Ionic liquid buffer In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises an ionic liquid buffer. The ionic liquid buffer consists of anions and cations. In one embodiment, the buffer composition comprises (i) anions derived from Good's buffer (such as those listed in Figure 1), α-amino acids (such as natural α-amino acids including proline, hydroxyproline, cysteine, leucine, histidine, and citrulline), β-amino acids (such as those listed above), aminosulfonic acids (such as those including BES and taurine), or aminosulfinic acids (such as those listed above), and (ii) tetraalkylammonium (Colinium, [Me2N(CH2CH2OH)2] + The ionic liquid buffer comprises a cation selected from tetramethylammonium, tetraethylammonium, or tetrabutylammonium (e.g., tetramethylammonium, tetraethylammonium, or tetrabutylammonium), dialkylimidazolium (e.g., 1-ethyl-3-methylimidazolium or 1-butyl-3-methylimidazolium), alkylpyridinium (e.g., methylpyridinium), alkylpyrrolidinium (e.g., N-butyl-N-methylpyrrolidinium), or tetraalkylphosphonium (e.g., tetrabutylphosphonium or tributylmethylphosphonium) cations. In one embodiment, the buffer composition comprises an ionic liquid buffer comprising (i) an anion derived from Good's buffer (particularly tricine, TES, CHES, HEPES, BES, or MES), and (ii) a cholinium cation. Alternatively, the anion may be FeCl4 - NH2SO3 -, bis(trifluoromethylsulfonyl)imide, halides (chlorides, bromides, or iodides, etc.), carboxylic acids (acetic acid, methoxyacetic acid, trifluoroacetic acid, trichloroacetic acid, oxalic acid, propionic acid, malonic acid, lactic acid, pyruvic acid, pivalic acid, benzoic acid, salicylic acid, caprylic acid, capric acid, palmitic acid, stearic acid, or heptafluorobutonic acid, etc.), sulfuric acid (alkyl sulfuric acid (methyl sulfate or ethyl sulfate, etc.)), sulfonic acid (alkyl sulfuric acid (methanesulfonic acid, trifluoromethanesulfonic acid, or hydroxymethanesulfonic acid, etc.)) The cation may be ammonium ([Me2NH(CH2CH2OH)]+, etc.), pentaalkylguanidinium (N,N,N',N',N"-pentamethylguanidinium, etc.), dialkylmorpholinium (ethylmethylmorpholinium, etc.), or tris(perfluoroalkyl)trifluorophosphate (tris(pentafluoroethyl)trifluorophosphate, etc.)), or phosphorous acid (alkyl hydrogen phosphite (methyl hydrogen phosphite, etc.), or dialkyl hydrogen phosphite (dimethyl hydrogen phosphite, etc.), etc.). The cation may be ammonium ([Me2NH(CH2CH2OH)]+, etc.), pentaalkylguanidinium (N,N,N',N',N"-pentamethylguanidinium, etc.), dialkylmorpholinium (ethylmethylmorpholinium, etc.), or alkylpyrimidinium (methylpyrimidinium, etc.) cations.
[0182] In one embodiment of the first or third aspect of the present invention, the ionic liquid buffer is used in an aqueous composition such as an aqueous solution. In another embodiment of the first or third aspect of the present invention, the ionic liquid buffer is used in a non-aqueous culture medium. In another embodiment of the first or third aspect of the present invention, the ionic liquid buffer itself is used as a culture medium.
[0183] In one embodiment of the second, fourth, or fifth aspect of the present invention, the ionic liquid buffer is used in an aqueous solution.
[0184] Ionic liquid buffers can be prepared as described by MacFarlane et al (Chemical Communications, 2010, vol 46, pages 7703-7705), Matias et al (RSC Advances, 2014, vol 4, 15597-15601), Taha et al (Green Chemistry, 2014, vol 16(6), pages 3149-3159), or Taha et al (Chemistry, 2015, vol 21(12), pages 4781-4788). All of these publications are incorporated herein by reference in their entirety. For example, choline hydroxide can be reacted with Good's buffer to prepare an ionic liquid buffer.
[0185] Amount of buffering agent In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, buffering groups (or more) of Good's buffer, N-substituted aminosulfonic acid (such as BES), N-unsubstituted aminosulfonic acid (such as taurine), aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl (such as imidazole), phenolic acid, amino acid (such as proline), peptide, peptide equivalent, urea, or polymer buffer are present in the composition of the present invention at a concentration of 1 to 500 mmol / L, or 1 to 200 mmol / L, or 1 to 100 mmol / L, or 1 to 50 mmol / L, or 1 to 12 mmol / L.
[0186] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, when two or more of these buffers are used in the composition of the present invention, that is, when two or more Good's buffers, aminosulfonic acids, aminosulfinic acids, phosphates, phosphorous acids, heteroaryls, phenolic acids, amino acids, peptides, peptide equivalents, urea, or polymer buffers are used, the total concentration of the buffer or buffer group present in the composition is 1 to 500 mmol / L, or 1 to 200 mmol / L, or 1 to 100 mmol / L, or 1 to 50 mmol / L, or 1 to 12 mmol / L.
[0187] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, at least 700 μl of a 1 M HCl aqueous solution (typically at least 1000 μl of a 1 M HCl aqueous solution, more typically at least 1300 μl of a 1 M HCl aqueous solution) is required to change the pH of 100 mL of the composition by 1 unit at 20°C.
[0188] In another embodiment of the first, second, third, fourth, or fifth aspect of the present invention, at least 200 μl of a 1 M NaOH aqueous solution (typically at least 250 μl of a 1 M NaOH aqueous solution, more typically at least 300 μl of a 1 M NaOH aqueous solution) is required to change the pH of 100 mL of the composition by 1 unit at 20°C.
[0189] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition of the present invention has a buffering capacity of at least 0.002, preferably at least 0.01, preferably at least 0.02 at 20°C.
[0190] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the buffer used in the composition of the present invention is pharmaceutically acceptable. In one embodiment, the buffer used in the composition of the present invention is listed on the FDA (U.S. Food and Drug Administration) GRAS (Generally Recognized as Safe) list.
[0191] In preferred embodiments of the first, second, third, fourth, or fifth aspects of the present invention, the composition is an aqueous composition comprising the following: (i) One or more components selected from BES, imidazole, and taurine; (ii) Bicarbonate ions or their equivalents; and (iii) α- or β-amino acids as needed (e.g., natural α-amino acids such as proline, hydroxyproline, cysteine, leucine, histidine, or citrulline).
[0192] In the first particularly preferred embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising (i) BES; and (ii) bicarbonate ions or equivalents thereof. Preferably, the composition is an aqueous composition comprising (i) BES; and (ii) bicarbonate ions. Preferably, the aqueous composition further comprises zinc ions.
[0193] In a second particularly preferred embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising (i) imidazole; and (ii) bicarbonate ions or equivalents thereof. Preferably, the composition is an aqueous composition comprising (i) imidazole; and (ii) bicarbonate ions. Preferably, the aqueous composition further comprises zinc ions.
[0194] In the third particularly preferred embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising (i) imidazole; (ii) an α- or β-amino acid (e.g., a natural α-amino acid such as proline); and (iii) a bicarbonate ion or its equivalent. Preferably, the composition is an aqueous composition comprising (i) imidazole; (ii) an α- or β-amino acid (e.g., a natural α-amino acid such as proline); and (iii) a bicarbonate ion. Preferably, the aqueous composition further comprises a zinc ion.
[0195] In the fourth particularly preferred embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising (i) imidazole; (ii) taurine; and (iii) bicarbonate ions or equivalents thereof. Preferably, the composition is an aqueous composition comprising (i) imidazole, (ii) taurine, and (iii) bicarbonate ions. Preferably, the aqueous composition further comprises zinc ions.
[0196] In the fifth particularly preferred embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising (i) taurine and (ii) bicarbonate ions or equivalents thereof. Preferably, the composition is an aqueous composition comprising (i) taurine and (ii) bicarbonate ions. Preferably, the aqueous composition further comprises zinc ions.
[0197] In a sixth particularly preferred embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising (i) taurine; (ii) an α- or β-amino acid (e.g., a natural α-amino acid such as proline); and (iii) a bicarbonate ion or its equivalent. Preferably, the composition is an aqueous composition comprising (i) taurine, (ii) an α- or β-amino acid (e.g., a natural α-amino acid such as proline), and (iii) a bicarbonate ion. Preferably, the aqueous composition further comprises a zinc ion.
[0198] In the seventh particularly preferred embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising (i) imidazole; (ii) taurine; (iii) an α- or β-amino acid (e.g., a natural α-amino acid such as proline); and (iv) a bicarbonate ion or its equivalent. Preferably, the composition is an aqueous composition comprising (i) imidazole, (ii) taurine, (iii) an α- or β-amino acid (e.g., a natural α-amino acid such as proline); and (iv) a bicarbonate ion. Preferably, the aqueous composition further comprises a zinc ion.
[0199] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition contains calcium ions present at a concentration of 0.1 to 2.5 mmol / L, or 1 to 2.5 mmol / L, or 1.1 to 1.4 mmol / L, or about 1.25 mmol / L. In one embodiment, at least some calcium ions are supplied by dissolving calcium chloride, calcium sulfate, calcium acetate, or calcium ascorbate in water. In another embodiment, at least some calcium ions are supplied by dissolving calcium chloride in water. In yet another embodiment, almost all calcium ions are supplied by dissolving calcium chloride in water.
[0200] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition contains magnesium ions present at a concentration of 0.1 to 2.5 mmol / L, or 0.2 to 0.6 mmol / L, or 0.3 to 0.5 mmol / L, or about 0.45 mmol / L. In one embodiment, at least some of the magnesium ions are supplied by dissolving magnesium chloride, magnesium sulfate, magnesium acetate, or magnesium ascorbate in water. In another embodiment, at least some of the magnesium ions are supplied by dissolving magnesium chloride in water. In yet another embodiment, almost all of the magnesium ions are supplied by dissolving magnesium chloride in water.
[0201] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, calcium ions and magnesium ions are present in a molar concentration ratio of 5:1 to 1:1 (calcium ions:magnesium ions), or a molar concentration ratio of 4:1 to 2:1, or about 3:1.
[0202] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, calcium ions are present at a concentration of 1 to 2.5 mmol / L, and magnesium ions are present at a concentration of 0.2 to 0.6 mmol / L. In another embodiment, calcium ions are present at a concentration of 1.1 to 1.4 mmol / L, and magnesium ions are present at a concentration of 0.3 to 0.5 mmol / L.
[0203] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition contains bicarbonate ions present at concentrations of 1 to 45 mmol / L, 10 to 40 mmol / L, about 21 to 35 mmol / L, about 22 to 29 mmol / L, or about 25 mmol / L. The ranges of 1 to less than 21 mmol / L and greater than 35 to 45 mmol / L are less preferred but still within the scope of the present invention. In one embodiment, at least some bicarbonate ions are supplied by dissolving sodium bicarbonate, potassium bicarbonate, sodium carbonate, or potassium carbonate in water. In another embodiment, at least some bicarbonate ions are supplied by dissolving sodium bicarbonate in water. In yet another embodiment, almost all bicarbonate ions are supplied by dissolving sodium bicarbonate in water.
[0204] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition contains an equivalent of a bicarbonate ion. In one embodiment, the equivalent of a bicarbonate ion is a compound that can be converted to a bicarbonate ion (e.g., by hydrolysis). In one embodiment, the equivalent of a bicarbonate ion is an acetate ion. While not bound by theory, at present it is assumed that acetate ions are converted to bicarbonate ions in vivo. In one embodiment, acetate ions are present at concentrations of 1 to 45 mmol / L, or 10 to 40 mmol / L, or about 21 to 35 mmol / L, or about 22 to 29 mmol / L, or about 25 mmol / L. The ranges of 1 to less than 21 mmol / L and greater than 35 to 45 mmol / L are less preferred but still within the scope of the present invention. In one embodiment, at least some acetate ions are supplied by dissolving sodium acetate, zinc acetate, potassium acetate, calcium acetate, magnesium acetate, or ferrous acetate in water. In one embodiment, at least some acetate ions are supplied by dissolving sodium acetate or zinc acetate in water. In another embodiment, almost all acetate ions are supplied by dissolving sodium acetate in water.
[0205] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition comprises bicarbonate ions and equivalents of bicarbonate ions, such as acetate ions. In one embodiment, bicarbonate ions and acetate ions are present together at concentrations of 1 to 45 mmol / L, or 10 to 40 mmol / L, or about 21 to 35 mmol / L, or about 22 to 29 mmol / L, or about 25 mmol / L. The ranges of 1 to less than 21 mmol / L and greater than 35 to 45 mmol / L are less preferred but still within the scope of the present invention.
[0206] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition contains potassium ions present at concentrations of 2.5 to 200 mmol / L, or 2.5 to 100 μ mmol / L, or 2.5 to 50 mmol / L, or 2.5 to 20 mmol / L, or 2.5 to 6.2 mmol / L, 3 to 6 mmol / L, or about 5 mmol / L. In one embodiment, at least some potassium ions are supplied by dissolving potassium chloride, potassium sulfate, potassium acetate, potassium ascorbate, potassium bicarbonate, or potassium carbonate in water. In another embodiment, at least some potassium ions are supplied by dissolving potassium chloride, potassium sulfate, or potassium acetate in water. In yet another embodiment, almost all potassium ions are supplied by dissolving potassium chloride in water.
[0207] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition contains chloride ions present at a concentration of 96 to 126 mmol / L, or 100 to 122 mmol / L, or about 118 mmol / L. In one embodiment, at least some of the chloride ions are supplied by dissolving calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride, ferrous chloride, ferric chloride, choline chloride, thiamine pyrophosphate chloride, and / or carnitine chloride in water. In one embodiment, at least some of the chloride ions are supplied by dissolving calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride, choline chloride, thiamine pyrophosphate chloride, and / or carnitine chloride in water.
[0208] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition contains sodium ions present at concentrations of 100 to 400 mmol / L, or 100 to 300 mmol / L, or 100 to 200 mmol / L, or 100 to 150 mmol / L, or 115 to 140 mmol / L, or about 135 mmol / L. In one embodiment, at least some sodium ions are supplied by dissolving sodium bicarbonate, sodium carbonate, sodium chloride, sodium sulfate, sodium acetate, or sodium ascorbate in water. In one embodiment, at least some sodium ions are supplied by dissolving sodium bicarbonate, sodium chloride, sodium sulfate, or sodium acetate in water. In another embodiment, at least some sodium ions are supplied by dissolving sodium bicarbonate and / or sodium chloride in water. In yet another embodiment, almost all sodium ions are supplied by dissolving sodium bicarbonate and / or sodium chloride in water.
[0209] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition contains zinc ions present at a concentration of 0.1 to 200 μmol / L, or 0.1 to 150 μmol / L, or 0.1 to 100 μmol / L, or 0.1 to 50 μmol / L, or 1 to 10 μmol / L. In one embodiment, at least some zinc ions are supplied by dissolving zinc chloride, zinc sulfate, zinc acetate, zinc phosphate (such as Zn3(PO4)2, ZnHPO4, or Zn(H2PO4)2), zinc phosphite (such as Zn3(PO3)2, ZnHPO3, or Zn(H2PO3)2), zinc ascorbate, zinc gluconate, zinc oxide, zinc pivalate, zinc picolinate, or zinc pyrithione in water. In one embodiment, at least some zinc ions are supplied by dissolving zinc chloride in water. In another embodiment, almost all zinc ions are supplied by dissolving zinc chloride in water. In one embodiment, at least some zinc ions are supplied together with thymulin or in the form of a zinc-thymulin complex. In one embodiment, almost all zinc ions are supplied together with thymulin or in the form of a zinc-thymulin complex.
[0210] Intracellular zinc ions (Zn 2+The concentration can be increased with zinc ions such as ascorbate ions, calcimycin, chloroquine, hydroxychloroquine, cryoquinol, diiodohydroxyquinoline, dithiocarbamates (such as pyrrolidinedithiocarbamate), epigallocatechin gallate, hinokitiol, PBT2, pyrithione, quercetin, or gincophorin. Accordingly, in one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises zinc ions and further comprises a zinc ionophore. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises zinc ions and further comprises ascorbate ions, calcimycin, chloroquine, hydroxychloroquine, cryoquinol, diiodohydroxyquinoline, dithiocarbamate (such as pyrrolidinedithiocarbamate), epigallocatechin gallate, hinokitiol, PBT2, pyrithione, quercetin, or gincophorin. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises zinc ions and further comprises pyrithione. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises zinc pyrithione. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises zinc ascorbate.
[0211] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises transferrin present at a concentration of 1 to 100 μmol / L, or 1 to 50 μmol / L, or 1 to 25 μmol / L. The transferrin may be used in the form of holotransferrin, apotransferrin, or monopheric transferrin.
[0212] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition contains iron ions present at a concentration of 1 to 100 μmol / L, or 10 to 100 μmol / L. The iron ions are Fe 2+ Or Fe 3+It can be used in the following forms. In one embodiment, at least some iron ions are supplied by dissolving ferrous fumarate, ferrous gluconate, ferrous succinate, ferrous sulfate, ammonium iron citrate, iron glycinate, ferric nitrate, ferrous acetate, ferrous ascorbate, ferrous chloride, or ferric chloride in water.
[0213] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition further comprising one or more of the following: (a) Glucose 2-11 mmol / L; (b) Glycerol in a concentration of 50-150 μmol / L; (c) Choline ions in concentrations of 7-15 μmol / L; (d) Glutamic acid at a concentration of 5-400 μmol / L; (e) Aspartic acid in a concentration of 5-200 μmol / L; (f) Glutamine at a concentration of 100-2000 μmol / L; (g) 20-215 μmol / L pyroglutamic acid; (h) Arginine at 20-200 μmol / L; (i) Thiamine pyrophosphate ions in concentrations of 1 to 250 nanomoles / L; (j) Carnitine at 40-100 μmol / L; (k) 5-600 mIU / L of porcine or human insulin; (l) Hyaluronic acid at a concentration of 20-200 μmol / L; (m) Transferrin in a concentration of 1 to 100 μmol / L; (n) 20-250 μmol / L of leucine; (o) Linoleic acid at a concentration of 10-100 μmol / L; (p) Cholesterol at 200-1000 μmol / L; (q) Pyridoxal-5-phosphate in a concentration of 20-500 μmol / L; or (r) Chitosan at a concentration of 10-250 μmol / L.
[0214] In one embodiment, if the composition of the first, second, third, fourth, or fifth embodiment of the present invention contains glucose, it may be used in the form of D-glucose. In one embodiment, if the composition of the first, second, third, fourth, or fifth embodiment contains glutamic acid, it may be used in the form of L-glutamic acid. In one embodiment, if the composition of the first, second, third, fourth, or fifth embodiment contains aspartic acid, it may be used in the form of L-aspartic acid. In one embodiment, if the composition of the first, second, third, fourth, or fifth embodiment contains glutamine, it may be used in the form of L-glutamine. In one embodiment, if the composition of the first, second, third, fourth, or fifth embodiment contains carnitine, it may be used in the form of L-carnitine. In one embodiment, if the composition of the first, second, third, fourth, or fifth embodiment contains leucine, it may be used in the form of L-leucine.
[0215] In one embodiment, if the composition of the first, second, third, fourth, or fifth aspect of the present invention contains insulin, this may be human insulin, such as human recombinant insulin.
[0216] In one embodiment, if the composition of the first, second, third, fourth, or fifth aspect of the present invention contains choline ions, thiamine pyrophosphate and / or carnitine, they may be supplied to the composition independently as chloride salts, sulfates, acetates, or other salts. In one embodiment, chloride salts are used.
[0217] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises one or more of hyaluronic acid, transferrin, leucine, linoleic acid, cholesterol, or pyridoxal-5-phosphate. Currently, these components are thought to be able to preserve cell membrane function.
[0218] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition comprises chitosan. Chitosan can function as an antifungal and antimicrobial agent. Chitosan can also function as a buffer, thickening agent or gelling agent, or Toll-like receptor modulator.
[0219] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (a) 1 to 12 mmol / L of N-substituted aminosulfonic acid (preferably BES); and (b) Bicarbonate ions in a concentration of 21-35 mmol / L.
[0220] In this embodiment, the composition may further optionally contain one or more additional components selected from zinc ions, calcium ions, magnesium ions, potassium ions, chloride ions, sodium ions, glucose (preferably D-glucose), glycerol, choline ions, glutamic acid (preferably L-glutamic acid), aspartic acid (preferably L-aspartic acid), glutamine (preferably L-glutamine), carnitine (preferably L-carnitine), thiamine pyrophosphate ions, and porcine or human insulin (recombinant human insulin).
[0221] In another embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (a) 1 to 12 mmol / L of N-substituted aminosulfonic acid (preferably BES); (b) 21-35 mmol / L of bicarbonate ions; and (c) Zinc ions in a concentration of 0.1 to 200 μmol / L.
[0222] In this embodiment, the composition may further optionally contain one or more additional components selected from calcium ions, magnesium ions, potassium ions, chloride ions, sodium ions, glucose (preferably D-glucose), glycerol, choline ions, glutamic acid (preferably L-glutamic acid), aspartic acid (preferably L-aspartic acid), glutamine (preferably L-glutamine), carnitine (preferably L-carnitine), thiamine pyrophosphate ions, and porcine or human insulin (recombinant human insulin).
[0223] In another embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (a) 1 to 12 mmol / L of N-substituted aminosulfonic acid (preferably BES); (b) Calcium ions in a concentration of 0.1 to 2.5 mmol / L; (c) Magnesium ions at 0.02 to 2.5 mmol / L; (d) 21-35 mmol / L of bicarbonate ions; (e) 2.5 to 6.2 mmol / L of potassium ions; (f) Chloride ions at 96-126 mmol / L; (g) 100-150 mmol / L of sodium ions; and (h) Zinc ions in a concentration of 0.1 to 200 μmol / L, as needed.
[0224] In this embodiment, the composition may further optionally include one or more additional components selected from glucose (preferably D-glucose), glycerol, choline ions, glutamic acid (preferably L-glutamic acid), aspartic acid (preferably L-aspartic acid), glutamine (preferably L-glutamine), carnitine (preferably L-carnitine), thiamine pyrophosphate ions, and porcine or human insulin (recombinant human insulin).
[0225] In another embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (a) 1 to 12 mmol / L of N-substituted aminosulfonic acid (preferably BES); (b) Calcium ions in a concentration of 0.1 to 2.5 mmol / L; (c) Magnesium ions at 0.02 to 2.5 mmol / L; (d) 21-35 mmol / L of bicarbonate ions; (e) 2.5 to 6.2 mmol / L of potassium ions; (f) Chloride ions at 96-126 mmol / L; (g) 100-150 mmol / L of sodium ions; (h) 2 to 11 millimoles / L of glucose (preferably D-glucose); (i) Glycerol in a concentration of 50-150 μmol / L; (j) Choline ions 7-15 μmol / L; (k) 5-400 μmol / L of glutamic acid (preferably L-glutamic acid); (l) 5-200 μmol / L of aspartic acid (preferably L-aspartic acid); (m) 100-2000 μmol / L of glutamine (preferably L-glutamine); (n) 40-100 μmol / L of carnitine (preferably L-carnitine); (o) Thiamine pyrophosphate ions in concentrations of 1 to 250 nanomoles / L, as needed; (p) 5-600 mIU / L of porcine or human insulin (preferably recombinant human insulin), as needed; and (q) Zinc ions in concentrations of 0.1 to 200 μmol / L, as needed.
[0226] In another embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (a) N-substituted aminosulfonic acid (preferably BES) in a concentration of approximately 5 mmol / L; (b) 1.25 mmol / L of calcium ions; (c) Approximately 0.45 mmol / L of magnesium ions; (d) Approximately 25 mmol / L of bicarbonate ions; (e) Potassium ions at approximately 5 mmol / L; (f) Chloride ions at approximately 118-119 mmol / L; (g) Approximately 135 mmol / L of sodium ions; (h) Approximately 10 mmol / L of D-glucose; (i) Glycerol at approximately 110 μmol / L; (j) Choline ions at approximately 10 μmol / L; (k) L-glutamic acid at approximately 300 μmol / L; (l) L-aspartic acid at approximately 20 μmol / L; (m) L-glutamic acid at approximately 400 μmol / L; (n) L-carnitine at approximately 50 μmol / L; (o) Thiamine pyrophosphate ions at approximately 40 nanomoles / L, as needed; (p) Recombinant human insulin, approximately 28 mIU / L, as needed; (q) Approximately 50 μmol / L of zinc ions (or approximately 10 μmol / L of zinc ions), as needed; (r) If necessary, approximately 50 μmol / L of transferrin (or approximately 25 μmol / L of transferrin); (s) L-leucine, approximately 120 μmol / L, as needed; (t) Approximately 70 μmol / L of linoleic acid, as needed; (u) Cholesterol of about 400 μmol / L as needed; and (v) Approximately 100 μmol / L of pyridoxal-5-phosphate, if necessary.
[0227] In another embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) 1 to 500 mmol / L buffer (preferably a phosphate buffer, e.g., a combination of KH2PO4 and Na2HPO4); and (ii) 0.1 to 200 g / L of essential oils having antiviral activity (preferably clove oil, eucalyptus oil, basil oil, ginger oil, extracts or components of any of these, or combinations thereof).
[0228] In this embodiment, the composition may further include, as needed, one or more additional components selected from zinc ions (preferably ZnCl2), NaCl, KCl, MgCl2, NaHCO3, xylitol, EDTA, CaCl2, glycerol, HPMC, PEG400, poloxamer 188, benzalkonium chloride, and sodium hyaluronate.
[0229] In yet another embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) 1 to 500 mmol / L buffer solution (preferably a phosphate buffer solution, for example, a combination of KH2PO4 and Na2HPO4); (ii) 0.1 to 200 μmol / L of zinc ions (preferably ZnCl2); (iii) 0.1 to 50 g / L of clove oil or its extract or components; (iv) 0.1 to 50 g / L of eucalyptus oil or its extract or components; (v) 0.1 to 50 g / L of basil oil or its extract or components; and (vi) 0.1 to 50 g / L of ginger oil or its extract or component.
[0230] In this embodiment, the composition may further include, as needed, one or more additional components selected from NaCl, KCl, MgCl2, NaHCO3, xylitol, EDTA, CaCl2, glycerol, HPMC, PEG400, poloxamer 188, benzalkonium chloride, and sodium hyaluronate.
[0231] In yet another embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is an aqueous composition comprising the following: (i) 25-250 mmol / L of phosphate buffer, e.g., a combination of KH2PO4 and Na2HPO4; (ii) 0.1 to 50 μmol / L of zinc ions (preferably ZnCl2); (iii) 21-35 mmol / L of bicarbonate ions; (iv) 0.1 to 10 g / L of clove oil or its extract or components; (v) 0.1 to 10 g / L of eucalyptus oil or its extract or components; (vi) 0.1 to 10 g / L of basil oil or its extract or components; and (vii) 0.1 to 10 g / L of ginger oil or its extract or component.
[0232] In this embodiment, the composition may further include, as needed, one or more additional components selected from NaCl, KCl, MgCl2, xylitol, EDTA, CaCl2, glycerol, HPMC, PEG400, poloxamer 188, benzalkonium chloride, and sodium hyaluronate.
[0233] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an antioxidant. In one embodiment, the antioxidant is vitamin E or a derivative thereof (e.g., α-tocopherol polyethylene glycol 1000 succinate (TPGS), or α-tocopherol succinate), ascorbic acid, or sodium metabisulfite.
[0234] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an emulsifier. Preferably, the emulsifier is pharmaceutically acceptable or acceptable for use in food (see, for example, Encyclopedia for Food and Health, 2016, Elsevier, ScienceDirect, eds. Caballero, Finglas and Toldra, which is incorporated herein by reference in its entirety). Typically, emulsifiers are prepared by alcohol decomposition or direct esterification of fatty acids (e.g., acetic acid, citric acid, lactic acid, tartaric acid, monoacetyltartaric acid, diacetyltartaric acid, stearic acid, or linoleic acid) with polyols (e.g., glycerol, propylene glycol, or sorbitol). Further treatment by reaction with ethylene oxide or esterification with organic acids produces a wide range of emulsifiers with different properties. Typical emulsifiers include lecithin; mono and diglycerides of fatty acids and their esters; polyglycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters (polysorbate); propylene glycol fatty acid esters; sorbitan fatty acid esters (Span's); stearoyl lactylate; and sucrose esters.
[0235] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an activator. In one embodiment, the activator is an antibiotic, an antiviral agent, a nitric oxide producer, an immunoglobulin, a Toll-like receptor modulator, a proton pump inhibitor, a lipid, an immunostimulant, an anti-inflammatory agent, an antiseptic, or an antifungal agent.
[0236] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an antibiotic. In one embodiment, the antibiotic is chloramphenicol, streptomycin, penicillin, nanomycopulitin, macrolide antibiotics (e.g., azithromycin, erythromycin, clarithromycin, roxithromycin, fidaxomicin, or telithromycin), or triticum repen. In one embodiment, the antibiotic is present at a concentration of 10 to 150 mg / L, or 60 to 120 mg / L, or about 100 mg / L.
[0237] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an antiviral agent. In one embodiment, the antiviral agent is chlorpheniramine, carbinoxamine, oseltamivir, favipiravir, remdesivir, ribavirin, ritonavir, lopinavir, darunavir, D-xylose, dendrimer (such as SPL7013), or a peptidic viral fusion inhibitor. Inhibitors), peptidase inhibitors (such as cathepsin inhibitors), protease inhibitors, helicase inhibitors, antibodies (such as polyclonal or monoclonal antibodies, such as anti-CD3 monoclonal antibodies, such as foralumab), nanobodies (nanobodies that interfere with spike-ACE2 interactions, e.g., Nb6 or mNb6-tri, which are incorporated herein by reference in their entirety, https: / / doi.org / 10.1101 / 2020.08.08.238469), sulfated polysaccharides [carrageenans (kappa-carrageenan, iota-carrageenan, lambda-carrageenan, or Carragelose] (Registered Trademark), fucoidan, sulfated fucoidan, sulfated galactan, or sulfated glycosaminoglycans (heparin, 6-O-desulfated heparin, enoxaparin, or 6-O-desulfated enoxaparin, etc.), ivermectin, grapefruit seed extract, chloroquine or its derivatives or analogs (hydroxychloroquine, ferroquine, desethylamodiaquine or pyrimethamine, etc.), quinine or its salts, derivatives or analogs (quinidine or mefloquine, etc.), pyronaridine, alcohol (ethanol or isopropanol, etc.), aryl sulfonic acid or diazenylaryl sulfonic acid (Becht et al, J Gen Vir,1968,vol 2(2),pages 261-268;Akerfeldt et al,J Med Chem,1971,vol 14(7),pages 596-600;and Hoffmann et al,Front Microbiol,2017,vol 8,articleThese include those described in 205 (all of which are incorporated herein by reference in their entirety), povidone-iodine, hydrogen peroxide, surfactant, glycyrrhizin, 18β-glycyrrhetinic acid, licorice extract, reynoudiol, knotweed extract, loquat extract, pyrazofrine, cyclodextrin (such as mercaptoundecanesulfonic acid-modified cyclodextrin), terpenes (such as β-caryophyllene, eucalyptol, or citral), cannabidiol, oxymetazoline, xylometazoline, interferon, or mixtures thereof. In one embodiment, the antiviral agent is a fatty acid [saturated fatty acid (e.g., caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, or stearic acid), omega-3 unsaturated fatty acid (e.g., alpha-linolenic acid, eicosapentaenoic acid, or docosahexaenoic acid), omega-6 unsaturated fatty acid (e.g., linoleic acid, gamma-linolenic acid, or arachidonic acid), omega-7 unsaturated fatty acid (e.g., palmitoleic acid or heptadecenoic acid), or omega-9 unsaturated fatty acid (e.g., oleic acid or erucic acid)], or derivatives thereof (e.g., esters, amides, carbamates, or fluorinated derivatives), or mixtures thereof; in particular, in one embodiment, the antiviral agent is linoleic acid or a derivative thereof (e.g., esters, amides, carbamates, or fluorinated derivatives). The fatty acid is lipophilic and can be incorporated as micelles in the composition of the present invention. In one embodiment, the antiviral agent is a griffithsin polypeptide or an analogue (such as Q-griffithsin). In one embodiment, the antiviral agent is a polypeptide comprising SEQ ID NO: 1 (which is the same as SEQ ID NO: 3 disclosed in WO2007 / 064844, the whole of which is incorporated herein by reference) or a fragment thereof comprising at least eight consecutive amino acids, a nucleic acid encoding the polypeptide, or an antibody against the polypeptide. In a preferred embodiment, the antiviral agent is an essential oil having antiviral activity, such as clove oil (Syzygium aromaticum), basil oil (Ocimum basilicum), ginger oil (Zingiber officinale), or eucalyptus oil (Eucalyptus).globulus), saffron oil (Crocus sativus), cannabis oil (Cannabis sativa), tea tree oil (Melaleuca alternifolia), black seed oil (Nigella sativa), dill oil, dill seed oil, nutmeg oil, cinnamon oil, cinnamon oil, bay leaf oil, garlic oil, or geranium oil. In another preferred embodiment, the antiviral agent is eugenol, zingiberene, eucalyptol, jensenone, ursolic acid, caryophyllene, estragol, 1,8-cineole, camphor, thymol, eugenol epoxide, apigenin, linalool, rosmarinic acid, 6-gingerol, 6-shogaol, gingerenone A, crocetin, crocin, picrocrocin, safranal, kafranone, tetrahydrocannabinol, cannabidiol (or its metabolites) 7-Hydroxycannabidiol), cannabinol, tetrahydrocannabivarin, terpinen-4-ol, terpinolene, α-terpineol, thymoquinone, α-curcumene, β-sesquiphellandrene, α-farnesene, α-phellandrene, β-phellandrene, camphene, β-bisabolene, α-terpinene, γ-terpinene, p-cymene, α-pinene, or palmitoleic acid (16:1 n-7), heptadecenoic acid (17:1 n-7), oleic acid (18:1 n-9), linoleic acid (18:2 n-6), α-linolenic acid (18:3 n-3), γ-linolenic acid (18:3 n-6), arachidonic acid (20:4 n-6), or erucic acid (22:1 This is an antiviral agent that imparts antiviral activity to essential oils such as monounsaturated or polyunsaturated fatty acids, such as n-9). In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of antiviral agents other than essential oils or their extracts or components. In one embodiment, the composition is substantially free of antiviral agents other than clove oil, eucalyptus oil, basil oil, ginger oil, any of these extracts or components, or combinations thereof.
[0238] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, if the composition includes clove oil, basil oil, ginger oil, eucalyptus oil, saffron oil, hemp oil, tea tree oil, black seed oil, dill oil, dill seed oil, nutmeg oil, cinnamon oil, bay leaf oil, garlic oil, geranium oil, or a combination thereof, the total concentration of these oils in the composition is 0.1 to 100 g / L, or 0.1 to 50 g / L, or 0.1 to 40 g / L, or 0.1 to 25 g / L, or 0.1 to 20 g / L, or 0.5 to 40 g / L, 0.5 to 25 g / L, or 1 to 20 g / L.
[0239] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises a nitric oxide (NO) producing agent. In one embodiment, the nitric oxide producing agent is S-nitroso-N-acetylpenicillamine, arginine, sodium pyruvate, serine, cysteine, lysine, quinine or its salts, derivatives, or analogs (such as quinidine or mefloquine), chloroquine or its derivatives or analogs (such as hydroxychloroquine, ferroquine, desethylamodiaquine, or pyrimethamine), denatonium salts such as denatonium benzoate, abscintine, salicin, phenylthiocarbamide, homoserine lactone, sesquiterpene lactone, sodium thiocyanate, linoleic acid, or derivatives thereof (such as esters, amides, carbamates, or fluoride derivatives), or 6-n-propylthiouracil.
[0240] Naturally occurring nitric oxide in the nasal cavity is a primary defense in humans. Nitric oxide is necessary to kill invading viruses and to prevent / reduce the rate and extent of infection and viral replication by viruses such as rhinovirus, influenza virus, and coronavirus. Accordingly, in one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises a nitric oxide donor such as S-nitroso-N-acetylpenicillamine. Nitric oxide is produced in vivo by the action of nitric oxide synthase, which catalyzes nitric oxide production from L-arginine. Accordingly, in one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises compounds such as arginine (typically L-arginine, usually in an amount of about 40 to 140 μmol / L), sodium pyruvate (usually in an amount of about 10 to 115 μmol / L), serine (typically L-serine, usually in an amount of about 25 to 160 μmol / L), cysteine (typically L-cysteine, usually in an amount of about 1 to 110 μmol / L), or lysine (typically L-lysine, usually in an amount of about 45 to 205 μmol / L), which stimulate or enable nitric oxide production in the nasal mucosa. The bitter taste receptor agonist may stimulate bitter taste receptors on nasal epithelial cells and thereby stimulate nitric oxide production. Accordingly, in one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises a bitter taste receptor agonist such as quinine or a salt thereof, derivative or analogue (such as quinidine or mefloquine), chloroquine or a derivative or analogue (such as hydroxychloroquine, ferroquine, desethylamodiaquine or pyrimethamine), denatonium salts such as denatonium benzoate, absinthine, salicin, phenylthiocarbamide, homoserine lactone (such as C4HSL, C6HSL or C12HSL), sesquiterpene lactone, sodium thiocyanate, or 6-n-propylthiouracil.
[0241] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an immunoglobulin. In one embodiment, the immunoglobulin is an immunoglobulin IgY, such as chicken immunoglobulin IgY. In one embodiment, the immunoglobulin is a virus-specific immunoglobulin. In one embodiment, the immunoglobulin is a virus-specific immunoglobulin IgY, such as virus-specific chicken immunoglobulin IgY.
[0242] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises a Toll-like receptor modulator (TLR2, TLR3, or TLR4 modulator). In one embodiment, the Toll-like receptor modulator is chitosan, hyaluronic acid, hyaluronic acid degradation products, carrageenan (such as lambda-carrageenan), chloroquine or its derivatives or analogs (such as hydroxychloroquine, ferroquine, desethylamodiaquine, or pyrimethamine), quinine or its salts, derivatives, or analogs (such as quinidine or mefloquine), Pam2Cys or its derivatives or analogs, Pam3Cys or its derivatives or analogs, or mixtures thereof. Pam2Cys and Pam3Cys and their derivatives and analogs are highly lipophilic and can be incorporated as micelles in the composition of the present invention. In one embodiment, the Toll-like receptor modulator is a TLR3 modulator such as polyinosinic acid and / or polycytidylic acid and / or derivatives thereof, as disclosed, for example, in WO2018 / 091965. This patent is incorporated herein by reference in its entirety.
[0243] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises a proton pump inhibitor. In one embodiment, the proton pump inhibitor is omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole, or iraprazole.
[0244] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises a lipid. In one embodiment, the lipid is sphingosine or an analogue thereof.
[0245] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an immunostimulant. In one embodiment, the immunostimulant is garlic or echinacea.
[0246] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an anti-inflammatory agent. In one embodiment, the anti-inflammatory agent is chamomile or violet.
[0247] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises a preservative. In one embodiment, the preservative is cetylpyridinium chloride.
[0248] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition further comprises an antifungal agent. In one embodiment, the antifungal agent is chitosan, posaconazole, nanomycopritin, or amphotericin B.
[0249] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition further comprises a thickening agent or a gelling agent. In one embodiment, the thickening or gelling agent is selected from polyethylene glycol (such as PEG400), microcrystalline cellulose, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, monoglycerides, diglycerides, locust bean gum, polyvinylpyrrolidone, alginates, chitosan, agarose, gellan gum, and carrageenan (kappa-carrageenan, iota-carrageenan, lambda-carrageenan, or Carragelose®). While not bound by theory, it is currently believed that the thickening or gelling agent may help the composition adhere to the target cell membrane during use. In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition is substantially carbomer-free. In one embodiment, the composition is substantially carrageenan-free. In one embodiment, the composition is substantially free of thickening agents or gelling agents.
[0250] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of citrate buffer. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of lactate buffer. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of phosphate buffer. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of borate buffer. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of glycine buffer. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of citric acid, lactic acid, phosphoric acid, phosphorous acid, boric acid, and glycine buffer. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of any buffer other than Good's buffer. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of any buffer other than N-substituted aminosulfonic acid buffer.
[0251] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of serum and / or serum extracts.
[0252] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of colloid osmotic substances. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of plasma supplementation solution. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of dextran. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of pyruvate. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is substantially free of phosphonoacetic acid.
[0253] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, or ionic liquid buffer is an aqueous solution with a pK of 6.7 to 7.9 at 37°C, or 6.7 to 7.7 at 37°C, or 7.1 to 7.5 at 37°C. a It has a value. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the N-substituted aminosulfonic acid has a pK of 7.1 to 7.5 in aqueous solution at 37°C. a It has a value.
[0254] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition has a pH of 6.7 to 7.9 at 37°C. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition has a pH of 6.7 to 7.7 at 37°C. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition has a pH of 7.0 to 7.5 at 37°C.
[0255] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is non-colloidal. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition has a viscosity of 0.1 to 99 centipoise, typically 0.1 to 90 centipoise, typically 0.2 to 80 centipoise, typically 0.2 to 70 centipoise, typically 0.3 to 60 centipoise, typically 0.3 to 50 centipoise, typically 0.4 to 40 centipoise, typically 0.4 to 30 centipoise, typically 0.5 to 20 centipoise, typically 0.5 to 10 centipoise, and typically 0.9 to 3.1 centipoise at 20°C. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition has a viscosity of 3.1 to 99 centipoise at 20°C, typically 3.1 to 90 centipoise, typically 3.1 to 80 centipoise, typically 3.1 to 70 centipoise, typically 3.1 to 60 centipoise, typically 3.1 to 50 centipoise, typically 3.1 to 40 centipoise, typically 3.1 to 30 centipoise, typically 3.1 to 20 centipoise, and typically 3.1 to 10 centipoise. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition has a molar osmotic pressure concentration of 268 to 290 milliosmoles / L, or a molar osmotic pressure concentration of 275 to 289 milliosmoles / L. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition has a molar osmotic concentration of 268 to 298 milliosmoles / L. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is isotonic with human serum (about 290 milliosmoles / L). In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition has a conductivity of 12.1 to 14.3 mS / cm. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the conductivity of the composition is equivalent to that of human serum (about 12.6 mS / cm).
[0256] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition is a composition comprising a solution, suspension, dispersion, mixture, or emulsion, or microdroplets. Typically, the composition is an aqueous composition. In one embodiment, the composition is an aqueous solution, aqueous suspension, aqueous dispersion, aqueous mixture, or aqueous emulsion, or an aqueous composition comprising microdroplets. In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition is provided in the form of a cream, emulsion, or ointment.
[0257] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is sterile. In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is pharmaceutically acceptable.
[0258] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is virtidative against coronaviruses (such as MERS-CoV, SARS-CoV, or SARS-CoV-2) or influenza viruses (such as influenza A virus (H1N1), influenza B virus, influenza C virus, or parainfluenza virus).
[0259] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is suitable for inhibiting proteases (e.g., cathepsin L, 3Cl, furin, or DPP4).
[0260] In one embodiment of the first, second, third, fourth, or fifth aspect of the present invention, the composition is suitable for suppressing the interaction between the spike protein of a coronavirus (such as MERS-CoV, SARS-CoV, or SARS-CoV-2) and a host receptor (such as the ACE2 receptor).
[0261] In one embodiment of a second or fifth aspect of the present invention, an aqueous composition is suitable for use in the treatment, preventive treatment or recovery from an airborne viral infection, or for use in reducing or preventing (usually reducing) viral replication in a subject infected with an airborne virus, or in a subject exposed to an airborne virus that can cause an airborne viral infection in the subject.
[0262] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition is suitable for inhalation into the oral cavity, upper respiratory tract, lower respiratory tract, nasal cavity, pharynx, larynx, trachea, bronchi, or lungs. In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition is suitable for administration by inhaler, nebulizer, intranasal spray, oral spray, bronchial spray, nasal drops, nasal lavage, nasal irrigation, neti pot, nasal tampon insertion, gargling or mouthwash, or administration in the form of cream, gel, emulsion, ointment, or any combination thereof, and similar methods of application. In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition is suitable for application to masks or other facial coverings. In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition is suitable for use in a container configured to bubble an oxygen-containing gas through the composition before the subject inhales the gas. In one embodiment, the composition is contained in a container through which an oxygen-containing gas is bubbling before the subject inhales the gas. In one embodiment, the container may be part of a ventilator or medical oxygen supply system, and typically the oxygen-containing gas contains about 95% oxygen and about 5% carbon dioxide. In another embodiment, the container may be part of an air conditioning system, and typically the oxygen-containing gas is air. In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the composition is suitable for diffusion or spraying into the air before the subject inhales the air. The air may be the air in a building (e.g., a hotel, office, or retail, theater, or arena) or a vehicle (e.g., a car, truck, bus, tram, airplane, train, boat, or large ship).
[0263] In one embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the wind-borne viral infection is caused by an RNA virus such as coronavirus, influenza virus, rhinovirus, measles virus, mumps virus, rubella virus, or human respiratory multinucleate virus. In one embodiment, the wind-borne viral infection is caused by an RNA virus such as coronavirus, influenza virus, rhinovirus, measles virus, or mumps virus. In one embodiment, the wind-borne viral infection is caused by a coronavirus selected from MERS-CoV, SARS-CoV, and SARS-CoV-2. In a preferred embodiment, the wind-borne viral infection is caused by SARS-CoV-2. In one embodiment, the wind-borne viral infection is caused by an influenza virus selected from influenza A virus, influenza B virus, influenza C virus, and parainfluenza virus.
[0264] In another embodiment of the first, second, third, fourth, or fifth aspects of the present invention, the wind-borne viral infection is caused by a DNA virus such as parvovirus B19, adenovirus, adeno-associated virus, herpesvirus, polyomavirus, or smallpox virus. In one embodiment, the wind-borne viral infection is caused by a DNA virus such as Epstein-Barr virus or parvovirus B19. In one embodiment, the wind-borne viral infection is caused by a herpesvirus selected from varicella-zoster virus (VZV or HHV-3), Epstein-Barr virus (EBV or HHV-4), human herpesvirus 6 (HHV-6A and HHV-6B), and human herpesvirus 7 (HHV-7). In one embodiment, the wind-borne viral infection is not caused by a herpesvirus. In one embodiment, the wind-borne viral infection is caused by a polyomavirus selected from BK polyomavirus and WU polyomavirus.
[0265] A sixth aspect of the present invention provides a method for preparing a composition according to the first, second, third, fourth, or fifth aspect of the present invention, the method comprising mixing all components with a solvent (preferably water), to a desired amount as needed, filtering as needed, and storing as needed in a sealed container. In one embodiment, the method further comprises stirring the composition, for example, by stirring or shaking. In one embodiment, the sealed container is sterile. In one embodiment, the sealed container is impermeable to oxygen, carbon dioxide, and water vapor.
[0266] A seventh aspect of the present invention provides a concentrate for preparing an aqueous composition of the first, second, third, fourth, or fifth aspect of the present invention, the concentrate comprising all components and water, and the concentrate can be diluted with water to form an aqueous composition of the first, second, third, fourth, or fifth aspect of the present invention. In one embodiment, the concentrate is concentrated 1 to 50 times, or 5 to 20 times, compared to the aqueous composition of the first, second, third, fourth, or fifth aspect of the present invention. In one embodiment, the concentrate is sterile.
[0267] In one embodiment, the concentrate of the seventh aspect of the present invention may be an aqueous concentrate comprising the following: (i) Good buffer in 10 to 1000 mmol / L (preferably 10 to 120 mmol / L), aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 1.0 to 25 mmol / L; (iii) Bicarbonate ions or equivalents in concentrations of 210 to 350 mmol / L; (iv) Potassium ions 25-62 mmol / L; (v) Chloride ions at 960-1260 mmol / L; (vi) 1000-1500 mmol / L of sodium ions; and (vii) Zinc ions in concentrations of 1 to 2000 μmol / L, as needed.
[0268] Naturally, in such embodiments, the concentrate can be diluted 10-fold with water to form an aqueous composition according to the first, second, third, fourth, or fifth embodiment of the present invention.
[0269] In another embodiment, the concentrate of the seventh aspect of the present invention may be an aqueous concentrate comprising: (i) N-substituted aminosulfonic acid in a concentration of 10 to 120 mmol / L; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 1.0 to 25 mmol / L; (iii) Bicarbonate ions in a concentration of 210-350 mmol / L; (iv) Potassium ions 25-62 mmol / L; (v) Chloride ions at 960-1260 mmol / L; (vi) 1000-1500 mmol / L of sodium ions; and (vii) Zinc ions in concentrations of 1 to 2000 μmol / L, as needed.
[0270] Naturally, in such embodiments, the concentrate can be diluted 10-fold with water to form an aqueous composition according to the first, second, third, fourth, or fifth embodiment of the present invention.
[0271] An eighth aspect of the present invention provides a concentrate for preparing an aqueous composition of the first, second, third, fourth, or fifth aspect of the present invention, the concentrate comprising all components except bicarbonate ions or their equivalents and their counter cations, and water, the concentrate can be diluted with water containing bicarbonate ions or their equivalents and their counter cations to form an aqueous composition of the first, second, third, fourth, or fifth aspect of the present invention. In one embodiment, the concentrate is concentrated 1 to 50 times, or 5 to 20 times, compared to the aqueous composition of the first, second, third, fourth, or fifth aspect of the present invention. In one embodiment, the concentrate is sterile. Water containing bicarbonate ions and their counter cations can be prepared by dissolving a bicarbonate salt, such as sodium bicarbonate, in water. Water containing bicarbonate ions and their counter cations can be prepared by dissolving a salt of the equivalent, such as sodium acetate, in water.
[0272] In one embodiment, the concentrate of the eighth aspect of the present invention may be an aqueous concentrate comprising the following: (i) Good buffer in 10 to 1000 mmol / L (preferably 10 to 120 mmol / L), aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 1.0 to 25 mmol / L; (iii) Potassium ions in 25-62 mmol / L; (iv) Chloride ions in concentrations of 960-1260 mmol / L; (v) 1000-1500 mmol / L of sodium ions; and (vi) Zinc ions in concentrations of 1 to 2000 μmol / L, as needed.
[0273] Naturally, in such embodiments, the concentrate may be diluted tenfold with water containing bicarbonate ions or equivalents and their countercations to form an aqueous composition according to the first, second, third, fourth, or fifth embodiment of the present invention.
[0274] In another embodiment, the concentrate of the eighth aspect of the present invention may be an aqueous concentrate comprising: (i) N-substituted aminosulfonic acid in a concentration of 10 to 120 mmol / L; (ii) Calcium ions and magnesium ions having a molar concentration ratio of 5:1 to 1:1, wherein the calcium ion concentration is 1.0 to 25 mmol / L; (iii) Potassium ions in 25-62 mmol / L; (iv) Chloride ions in concentrations of 960-1260 mmol / L; (v) 1000-1500 mmol / L of sodium ions; and (vi) Zinc ions in concentrations of 1 to 2000 μmol / L, as needed.
[0275] Naturally, in such embodiments, the concentrate may be diluted tenfold with water containing bicarbonate ions or equivalents and their countercations to form an aqueous composition according to the first, second, third, fourth, or fifth embodiment of the present invention.
[0276] A ninth aspect of the present invention provides a method for treating, preventing, or recovering from a target wind-borne viral infection, the method comprising administering an effective amount of a composition according to the first, second, third, fourth, or fifth aspect of the present invention to the target.
[0277] A ninth aspect of the present invention also provides a method for reducing or preventing (usually reducing) viral replication in a subject infected with an airborne virus, or a subject exposed to an airborne virus capable of causing an airborne viral infection in the subject, the method comprising administering an effective amount of a composition of the first, second, third, fourth, or fifth aspect of the present invention to the subject.
[0278] In one embodiment of the ninth aspect of the present invention, compositions of the first, second, third, fourth, or fifth aspects of the present invention are applied to the oral cavity, upper respiratory tract (including the nasal cavity, pharynx, and / or larynx) and / or lower respiratory tract (including the trachea, bronchi, and / or lungs) of a target by means of, for example, a spray, inhaler, nebulizer, intranasal spray, oral spray, bronchial spray, nasal drops, nasal lavage, nasal irrigation, neti pot, nasal tampon insertion, gargling or gargling, cream, gel, emulsion, ointment, or any combination thereof, and similar application methods. In one embodiment, the composition is applied once, twice, three times, four times, or more times a day. Although not bound by theory, it is currently considered that the bicarbonate ions in the composition can be replenished by carbon dioxide in the exhaled air during use of the composition. This may reduce the frequency of administration that would otherwise be necessary. While not intended to be constrained by theory, it is currently believed that the compositions of the present invention, although not precisely coating the target cell membrane, may similarly enter the interstitial fluid and enhance the effectiveness of the compositions.
[0279] In one embodiment of the ninth aspect of the present invention, the subject is a mammal, preferably a human.
[0280] In one embodiment of the ninth aspect of the present invention, the wind-borne viral infection is caused by an RNA virus such as coronavirus, influenza virus, rhinovirus, measles virus, mumps virus, rubella virus, or human respiratory polynuclear virus. In one embodiment, the wind-borne viral infection is caused by an RNA virus such as coronavirus, influenza virus, rhinovirus, measles virus, or mumps virus. In one embodiment, the wind-borne viral infection is caused by a coronavirus selected from MERS-CoV, SARS-CoV, and SARS-CoV-2. In a preferred embodiment, the wind-borne viral infection is caused by SARS-CoV-2. In one embodiment, the wind-borne viral infection is caused by an influenza virus selected from influenza A virus, influenza B virus, influenza C virus, and parainfluenza virus.
[0281] In another embodiment of the ninth aspect of the present invention, the wind-borne viral infection is caused by a DNA virus such as parvovirus B19, adenovirus, adeno-associated virus, herpesvirus, polyomavirus, or smallpox virus. In one embodiment, the wind-borne viral infection is caused by a DNA virus such as Epstein-Barr virus or parvovirus B19. In one embodiment, the wind-borne viral infection is caused by a herpesvirus selected from varicella-zoster virus (VZV or HHV-3), Epstein-Barr virus (EBV or HHV-4), human herpesvirus 6 (HHV-6A and HHV-6B), and human herpesvirus 7 (HHV-7). In one embodiment, the wind-borne viral infection is not caused by a herpesvirus. In one embodiment, the wind-borne viral infection is caused by a polyomavirus selected from BK polyomavirus and WU polyomavirus.
[0282] A tenth aspect of the present invention provides a method for reducing the risk of wind-borne viral infection in a subject, the method comprising applying a composition of the first, second, third, fourth, or fifth aspect of the present invention to a mask or other face covering. Typically, the composition is applied to a portion of the mask or face covering through which the subject breathes.
[0283] A tenth aspect of the present invention also provides a method for reducing the risk of airborne viral infection in a subject, the method comprising bubbling an oxygen-containing gas through a composition of the first, second, third, fourth, or fifth aspect of the present invention before the subject inhales the gas. Typically, the composition is contained in a container, and the oxygen-containing gas is bubbling through the composition in the container. In one embodiment, the container may be part of a ventilator or a medical oxygen supply system. In one embodiment, the oxygen-containing gas contains about 95% oxygen and about 5% carbon dioxide. In another embodiment, the container is part of an air conditioning system, and the oxygen-containing gas is air.
[0284] A tenth aspect of the present invention also provides a method for reducing the risk of wind-borne viral infection of a subject, the method comprising diffusing or spraying a composition of the first, second, third, fourth, or fifth aspect of the present invention into the air before the subject inhales the air. The air may be the air in a building (e.g., a hotel, office, or retail, entertainment, or sports venue) or a vehicle (e.g., a car, truck, bus, tram, airplane, train, boat, or large vessel).
[0285] An eleventh aspect of the present invention provides a spray, inhalant, sprayer, intranasal spray, oral spray, bronchial spray, nasal drop, nasal lavage agent, nasal irrigation agent, neti pot, nasal insertion tampon, gargle or mouthwash, container, cream, gel, emulsion, or ointment comprising (i) Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof, and (ii) an aqueous composition comprising a bicarbonate ion or an equivalent thereof.
[0286] An eleventh aspect of the present invention also provides a spray, inhalant, sprayer, intranasal spray, oral spray, bronchial spray, nasal drop, nasal lavage, nasal irrigation, neti pot, nasal insertion tampon, gargle or mouthwash, container, cream, gel, emulsion, or ointment, comprising an aqueous composition containing an N-substituted aminosulfonic acid and bicarbonate ions.
[0287] An eleventh aspect of the present invention also provides a spray, inhalant, sprayer, intranasal spray, oral spray, bronchial spray, nasal drop, nasal lavage, nasal irrigation, neti pot, nasal insertion tampon, gargle or mouthwash, container, cream, gel, emulsion, or ointment, comprising a composition of the first, second, third, fourth, or fifth aspect of the present invention.
[0288] An eleventh aspect of the present invention also provides a spray, inhalant, nebulizer, intranasal spray, oral spray, bronchial spray, nasal drop, nasal lavage, nasal irrigation, neti pot, nasal insertion tampon, gargle or mouthwash, container, cream, gel, emulsion, or ointment comprising (i) a concentrate of the seventh aspect of the present invention and (ii) water, wherein parts (i) and (ii) may be separate or together in the spray, inhalant, nebulizer, intranasal spray, oral spray, bronchial spray, nasal drop, nasal lavage, nasal irrigation, neti pot, nasal insertion tampon, gargle or mouthwash, container, cream, gel, emulsion, or ointment.
[0289] An eleventh aspect of the present invention also provides a spray, inhalant, nebulizer, intranasal spray, oral spray, bronchial spray, nasal drop, nasal lavage, nasal irrigation, neti pot, nasal insertion tampon, gargle or mouthwash, container, cream, gel, emulsion, or ointment comprising (i) a concentrate of the eighth aspect of the present invention, and (ii) water containing bicarbonate ions or their equivalents and their countercations, wherein parts (i) and (ii) may be separate or together in the spray, inhalant, nebulizer, intranasal spray, oral spray, bronchial spray, nasal drop, nasal lavage, nasal irrigation, neti pot, nasal insertion tampon, gargle or mouthwash, container, cream, gel, emulsion, or ointment.
[0290] A spray according to the eleventh aspect of the present invention can be used to apply a composition according to the first, second, third, fourth, or fifth aspect of the present invention to a mask or other facial covering.
[0291] A spray, nasal spray, oral spray, nasal drop, nasal lavage, nasal irrigation, neti pot, nasal insertion tampon, mouthwash or gargle, cream, gel, emulsion, or ointment according to the eleventh aspect of the present invention can be used to administer a composition according to the first, second, third, fourth, or fifth aspect of the present invention to the oral cavity and / or upper respiratory tract (including the nasal cavity, pharynx, and / or larynx) of a target.
[0292] An inhaler, nebulizer, or bronchial nebulizer according to an eleventh aspect of the present invention can be used to administer a composition according to the first, second, third, fourth, or fifth aspect of the present invention to the oral cavity, upper respiratory tract (including the nasal cavity, pharynx, and / or larynx), and / or lower respiratory tract (including the trachea, bronchi, and / or lungs) of a target. In one embodiment, the nebulizer is a mesh nebulizer (VMN), a jet nebulizer (JN), or an ultrasonic nebulizer. In one embodiment, the nebulizer is a mesh nebulizer (VMN).
[0293] A twelfth aspect of the present invention provides a mask or other facial covering material coated with or impregnated with an aqueous composition comprising (i) Good buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acids, peptides, peptide equivalents, polymer buffer, urea, ionic liquid buffer, or a combination thereof, and (ii) bicarbonate ions or equivalents.
[0294] A twelfth aspect of the present invention also provides a mask or other facial covering coated with or impregnated with an aqueous composition comprising an N-substituted aminosulfonic acid and bicarbonate ions.
[0295] A twelfth aspect of the present invention also provides a mask or other facial covering material coated with or impregnated with a composition of the first, second, third, fourth, or fifth aspect of the present invention.
[0296] In one embodiment of a twelfth aspect of the present invention, the mask or other face covering comprises an air permeable material, the air permeable material being coated with or impregnated with a composition, and the mask or other face covering is configured to allow the wearer to breathe through the air permeable material.
[0297] A thirteenth aspect of the present invention provides a method for cleaning an object, the method comprising applying a composition of the first, second, third, fourth, or fifth aspect of the present invention to the object. In a preferred embodiment, the composition comprises an essential oil or an extract or component having antiviral, antibacterial, or antifungal activity. Preferably, the essential oil or an extract or component thereof is selected from clove oil, eucalyptus oil, basil oil, ginger oil, saffron oil, hemp oil, tea tree oil, black seed oil, or an extract or component thereof. Preferably, the essential oil or an extract or component thereof is selected from clove oil, eucalyptus oil, basil oil, ginger oil, or an extract or component thereof. In a preferred embodiment, the composition further comprises a buffer.
[0298] The objects to be cleaned may be any objects for which it is desirable to remove or reduce the amount of viruses, bacteria, and / or fungi. Typical objects include pens, counters, shopping carts, tables, doorknobs, light switches, handles, handrails, railings, elevator buttons, desks, keyboards, telephones, toilets, faucets, sinks, and other objects that are or have high-frequency contact points.
[0299] In one embodiment of the first to thirteenth aspects of the present invention, the water used is distilled water. In another embodiment of the first to thirteenth aspects of the present invention, the water used is sterile water. In yet another embodiment of the first to thirteenth aspects of the present invention, the water used is ultrapure water.
[0300] definition In this invention, the term "anti-infective agent" includes antibacterial agents, antiviral agents, and antiviral agents, and the term "antibacterial agent" includes antibacterial agents and antifungal agents. The term "infectious disease" means a disease, disorder, or condition caused by an "infectious pathogen," which may be a bacterium, fungus, or virus.
[0301] "Virucidal" agents inactivate viruses by killing them or altering their surface structure, preventing them from entering host cells. If a drug prevents a virus from replicating, that drug is an "antiviral drug."
[0302] In this invention, "wind-borne viral infection" refers to an infectious disease transmitted by a wind-borne virus. A "wind-borne virus" is a virus whose disease is transmitted by particles in exhaled air. These particles include aerosols, which have a diameter of less than 5 micrometers and can remain wind-borne for extended periods, as well as larger droplets that can cause transmission over relatively short distances. Wind-borne viruses include (i) RNA viruses such as coronaviruses (e.g., MERS-CoV, SARS-CoV, and SARS-CoV-2), influenza viruses (e.g., influenza A virus, influenza B virus, influenza C virus, and parainfluenza virus), rhinoviruses, measles virus, mumps virus, rubella virus, and human respiratory polynuclear virus, as well as (ii) DNA viruses such as parvovirus B19, adenoviruses and adeno-associated viruses, herpesviruses (e.g., varicella-zoster virus (VZV or HHV-3), Epstein-Barr virus (EBV or HHV-4), human herpesvirus 6 (HHV-6A and HHV-6B), and human herpesvirus 7 (HHV-7)), polyomaviruses (e.g., BK polyomavirus and WU polyomavirus) and smallpox virus.
[0303] Wind-borne viral infections can cause a variety of diseases; for example, SARS-CoV-2 causes COVID-19, influenza viruses cause influenza, and various wind-borne viruses can cause viral tonsillitis.
[0304] As used herein, the term “treatment” means curative treatment and equivalent treatments to remission or palliative treatment. This term encompasses obtaining beneficial or desired physiological outcomes, which may or may not be clinically established. Beneficial or desired clinical outcomes include, but are not limited to, improvement of symptoms, prevention of symptoms, reduction of the severity of a viral infection, stabilization of a viral infection (i.e., no exacerbation), delay or slowing of the progression / exacerbation of a viral infection / symptoms, improvement or relief of a viral infection / symptoms, and remission (whether partial or whole), whether detectable or undetectable. As used herein, the term “recovery” means a reduction in the severity of a viral infection or symptoms and / or the occurrence of undesirable symptoms, and / or a slowing or prolongation of the course of progression, compared to not administering the composition of the present invention. As used herein, the term “preventive treatment” means prophylactic therapy and therapy that reduces the risk of developing a viral infection. The term “preventive treatment” encompasses both avoiding the occurrence of a viral infection and delaying the onset of a viral infection.
[0305] The "alkyl" group may be linear (i.e., straight-chain) or branched. Examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, and n-pentyl groups. Unless otherwise specified, the term "alkyl" does not include "cycloalkyl". Typically, alkyl groups are C1-C 12 It is an alkyl group. More typically, alkyl groups are C1-C6 alkyl groups. The "alkylene" group is similarly defined as a divalent alkyl group.
[0306] Unless otherwise specified, when a group is prefixed with the term "halo," such as a haloalkyl or halomethyl group, it should be understood that the group is substituted with one or more halo groups independently selected from fluoro, chloro, bromo, and iodine. Typically, the maximum number of halo substituents is limited only to the number of hydrogen atoms available for substitution in the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two, or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four, or five halo substituents. Similarly, unless otherwise specified, when a group is prefixed with a particular halo group, it should be understood that the group is substituted with one or more of that particular halo group. For example, the term "fluoromethyl" refers to a methyl group substituted with one, two, or three fluoro groups.
[0307] Similarly, when a group has the prefix "hydroxy," such as a "hydroxyalkyl" group, it should be understood that the group is substituted with one or more (e.g., 1, 2, 3, 4, or 5) hydroxyl groups.
[0308] The "alkenyl" group refers to an unsaturated alkyl group having one or more carbon-carbon double bonds. Examples of alkenyl groups include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and 1,4-hexadienyl groups. Unless otherwise specified, the term "alkenyl" does not include "cycloalkenyl". Typically, an alkenyl group is C2-C 12 It is an alkenyl group. More typically, an alkenyl group is a C2-C6 alkenyl group. The "alkenylene" group is similarly defined as a divalent alkenyl group.
[0309] The "alkynyl" group refers to an unsaturated alkyl group having one or more carbon-carbon triple bonds. Examples of alkynyl groups include ethynyl, propargyl, buta-1-inyl, and buta-2-inyl groups. Typically, an alkynyl group is C2-C 12 It is an alkynyl group. More typically, an alkynyl group is a C2-C6 alkynyl group. The "alkynylene" group is similarly defined as a divalent alkynyl group.
[0310] The "cycloalkyl" group refers to a saturated hydrocarbyl ring containing, for example, 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Unless otherwise specified, cycloalkyl groups can be monocyclic, bicyclic, or polycyclic hydrocarbyl rings.
[0311] The "cycloalkenyl" group refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carbon-carbon double bonds and containing, for example, 3 to 7 carbon atoms. Examples include cyclopenta-1-en-1-yl, cyclohexa-1-en-1-yl, and cyclohexa-1,3-dien-1-yl. Unless otherwise specified, cycloalkenyl groups can be monocyclic, bicyclic, or polycyclic hydrocarbyl rings.
[0312] A "heterocyclic group" is a non-aromatic cyclic group containing one or more carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms, such as N, O, or S, within a ring structure. Examples of heterocyclic groups include azethinyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, piperazinyl, dioxanyl, morpholinyl, and thiomorpholinyl groups. In one embodiment, the heterocyclic group has 4 to 7 members. In another embodiment, the heterocyclic group has 5 to 6 members.
[0313] A "heteroaryl group" is an aromatic cyclic group containing one or more carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms, such as N, O, or S, within a ring structure. Examples of heteroaryl groups include pyridinyl, pyridadinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl groups. In one embodiment, the heteroaryl group has 5 to 6 members.
[0314] The term "halo" includes fluoro, chloro, bromo, and iodine.
[0315] In this specification, when it is stated that a first atom or group is "directly bonded" to a second atom or group, it should be understood that the first atom or group is covalently bonded to the second atom without any intervening atoms or groups. For example, in the group -(C=O)N(CH3)2, the carbon atoms of each methyl group are directly bonded to the nitrogen atom, and the carbon atoms of the carbonyl group are directly bonded to the nitrogen atom, but the carbon atoms of the carbonyl group are not directly bonded to the carbon atoms of either methyl group.
[0316] A peptide contains two or more amino acids linked by a peptide bond. A peptide is a polymer containing two or more amino acid monomers. A peptide bond is an amide bond (-CO-NH-) formed between the carboxylic acid group of one amino acid and the amino group of another amino acid. In the present invention, a "peptide equivalent" may contain one or more amino acids, but it may also contain at least one amino acid equivalent, such as aminosulfonic acid or aminosulfinic acid. A peptide equivalent is a polymer containing one or more amino acid monomers, but it may also contain at least one amino acid equivalent monomer, such as aminosulfonic acid monomer or aminosulfinic acid monomer. Thus, a peptide equivalent has (i) a C-terminal amino acid equivalent or (ii) at least one bond that is not a peptide bond linking two monomers, for example, aminosulfonic acid is linked to another monomer by a sulfonamide bond (-SO2-NH-), or aminosulfinic acid is linked to another monomer by a sulfinamide bond (-SO-NH-).
[0317] In this invention, pH can be measured as detailed in European Pharmacopoeia 5.0, Volume 1, 2005, Section 2.2.3.
[0318] Buffering capacity (β) is H + and OH - The ability of a buffer composition to resist pH changes is quantified by absorbing or desorbing ions. When an acid or base is added to a buffer composition, the effect on pH changes can be large or small, depending on both the initial pH and the buffer composition's ability to resist pH changes. Buffering capacity (β) is defined as the value obtained by dividing the moles of acid or base required to change the pH of the buffer composition by 1 by the volume (liters) of the buffer composition; it is a unitless number.
[0319] While some components of the composition of the present invention are said to exist explicitly as ions (i.e., in ionic form) in the composition, it will be understood that many other components may also exist in ionic form in the composition of the present invention.
[0320] Any of the components of the composition of the present invention may exist in salt form.
[0321] Any of the components of the composition of the present invention are, but are not limited to, 12 C, 13 C, 1 H, 2 H(D), 14 N, 15 N, 16 O, 17 O, 18 O, 19 F and 127 Any stable isotope including I, and not limited to, 11 C, 14 C, 3 H(T), 13 N, 15 O, 18 F, 123 I, 124 I, 125 I and 131 It may contain any radioactive isotope including I. For example, histidine may be in the form of L-histidine-d3(α-d1, imidazole-2,5-d2).
[0322] In the present invention, "substantially all" means 98% or more by weight, or 99% or more by weight, or 99.5% or more by weight, or 99.9% or more by weight.
[0323] In the present invention, when a composition is said to be "substantially free" of a certain component, this means that the composition contains that component in amounts of 2% by weight or less, or 1% by weight or less, or 0.5% by weight or less, or 0.1% by weight or less.
[0324] In this invention, the "enantiomerically concentrated" isomer of a compound includes other isomers of the same compound in amounts less than 40% by weight. The "enantiomerically pure" isomer of a compound includes other isomers of the same compound in amounts less than 5% by weight, more typically less than 2% by weight, and most typically less than 0.5% by weight. [Brief explanation of the drawing]
[0325] [Figure 1] A list of the buffers of the present invention is shown. All buffers listed in Figure 1 are considered Good buffers. As shown in Figure 1, Good buffers can be classified into N-substituted aminosulfonic acid Good buffers and non-sulfonic acid Good buffers. [Figure 2] This report presents the analysis of SARS-CoV-2 proliferation curves in infected Vero cells treated with test buffer or control medium. 1 x 10⁵ Vero cells per well were pre-treated with test buffer or control medium for 1 hour, then infected with SARS-CoV-2 at a moi of 0.1. Adsorption was performed at 4°C. The infected monolayer was then washed twice with cold DMEM + 0.2% BSA, followed by incubation at 37°C for 1 hour in the presence of test buffer or control medium. After 1 hour, the monolayer was washed again with DMEM-2 (FBS 2%) to remove unbound viruses. Cells were incubated for the times indicated below, and viral production was collected to determine the amount for infectivity. Graphs were generated and statistical analysis performed using GraphPad Prism6 software. Data were plotted as mean ± SD from three replicated experiments; *p<0.05; ***p<0.001; ****p<0.0001. [Figure 3] The neutralization percentage of SARS-CoV-2 spike pseudotype reporter particles with various dilutions of test buffer compared to a control is shown. SARS-CoV-2 spike pseudotype reporter particles were incubated with various dilutions of test buffer or control at 37°C for 1 hour. Next, 4 x 10⁴ HuH7 cells (human hepatocytes) were added and incubated at 37°C for 72 hours. Infection rates were then determined by measuring luminescence / luciferase activity. [Figure 4]This graph shows the relationship between time and the amount of eugenol that permeated through the goat nasal mucosa when using four compositions (composition 7B containing eugenol, buffer, and zinc ions; composition 7D containing eugenol and buffer but without zinc ions; composition 7N containing eugenol and zinc ions but without buffer; and composition 7O containing eugenol but without buffer and zinc ions). The slope indicates the value of the steady-state flux (J).
[0326] Examples Example 1 A buffer solution was prepared by stirring the components listed in Table 1 in 1 L of sterile water. [Table 1]
[0327] Example 2 (An example based on a hypothesis) A buffer solution was prepared by stirring the components listed in Table 2 in 1 L of sterile water. [Table 2]
[0328] Example 3 (Example based on a hypothesis) The ability of the buffer to prevent or reduce viral infection of human bronchial epithelial cells can be tested using methods such as those described by Harcourt et al. (J Vis Exp, 2013, vol 72, e50157). In this disclosed method, a polarized layer of human airway epithelial Calu-3 cells can be prepared in a liquid-covered culture (LCC) in a Transwell.
[0329] LCC polarization can be assessed by measuring transepithelial electrical resistance (TEER) and / or sodium fluorescein equilibration (both methods as described by Harcourt et al.). Virus-induced depolarization of the cell layer can be assessed as described by Harcourt et al.
[0330] The LCC is washed in serum-free medium such as serum-free EMEM. The buffer is added to the base compartment of all test transwells. For the "uninfected" control group, the buffer is similarly added to the apical compartment of the appropriate transwell. For the "mock-infected" control group, the inactivated virus diluted in the buffer is added to the apical compartment of the appropriate transwell, and for the "viral-infected" test group, the virus diluted in the buffer is added to the apical compartment of the appropriate transwell.
[0331] The effect of the buffer on virus-induced depolarization of the cell layer can then be determined by measuring the equilibration of TEER and / or sodium fluorescein, as described by Harcourt et al.
[0332] Example 4 Buffer solutions A, B, C, and D were prepared by stirring the components listed in Table 3 in 1 L of ultrapure water (ATSM type I, 18.2 MΩ / cm at 25°C). [Table 3]
[0333] Example 5 - Antiviral test using buffer to evaluate inhibition of coronavirus entry Host: Vero-CCL81 Virus: SARS-CoV-2 (Stock titer: 1.67 x 10 in the tongue) 6 PFU / mL (PFU = plaque-forming unit)
[0334] I. Objective: Infection of Vero cells with SARS-CoV-2 in the presence or absence of a test buffer designed to prevent (or reduce) endosomal acidification and viral entry into cells.
[0335] II. Examination Design: 1. On the day before the experiment, 7e4 cells were seeded in each well of a 24-well plate. 24 hours later, immediately before infection, the coefficient cell count per well was 1e5 cells. 2. The Moi (infection multiplicity) used in the experiment was 0.1 (1 PFU per 10 cells). 3. One hour prior to infection, cells were pre-treated with test buffer or control medium by replacing the overlay medium (DMEM-10) with 0.5 mL of test buffer or control medium. 4. Adsorption was performed at 4°C using virus inoculum prepared in test buffer or control medium. The virus inoculum was prepared to have a calculated viral titer in 100 μL / well. 5. After adsorption, unbound viruses were removed by washing the monolayer twice with cold-bound buffer (DMEM + 0.2% BSA). 6. After adsorption, infected cells were incubated at 37°C for 1 hour in the presence of test buffer or control medium to synchronize infection and promote entry. 7. After 1 hour, the monolayer was washed three times with DMEM-2 (FBS 2%) (this is an additional step to remove unbound viruses). Subsequently, the monolayer was coated with 0.5 mL of DMEM-2 over the times indicated below to collect the viruses in the overlay and determine the amount for infectivity by plate assay in Vero cells. 8. Time points: Post-infection time (hpi) 1 (1 hour after incubation at 37°C), 3, 6, 24, and 48 hours. 9. Graphs were created and statistical analysis was performed using GraphPad Prism6 software. Data were plotted as mean ± SD from three repeated experiments; *p<0.05; ***p<0.001; ****p<0.0001.
[0336] III. Conditions: Test A. Medium = serum-free, low pH = 5.5, controlled control (negative control) ·Forcible entry Test B. Medium = serum-free, low pH + 100 mM NH4Cl (positive control) • Intrusion prevention Note: After treatment with low pH medium, Vero cells curled up and detached from the wells. Too many cells were lost because the protocol required many washing steps. The remaining cells were recovered after replacing the low pH medium with DMEM-2, but their total number differed too much for statistical comparison with other groups. A similar phenomenon was not observed with the test buffer, and Vero cells did not show signs of cytotoxicity after treatment with the test buffer. Test C. Culture medium = Buffer A from Example 4 Test D. Culture medium = Buffer B from Example 4 Test E. Culture medium = Buffer C of Example 4 Test F. Medium = Buffer D of Example 4 Test G. Medium = Non-infectious control - DMEM-2 • The haploid phase of Vero cells remained intact and showed no signs of damage or cytotoxicity after treatment with DMEM-2. Test H = Untreated control. Infection moi 0.1-DMEM-2 [Table 4]
[0337] IV. Virus: The amount of SARS-CoV-2 in Vero cells was determined on the day of the experiment. Plate count: 10 -4 Dilution (10x dilution): 19 PFU Infectious disease day titer: 1.9 x 10 6 PFU / ml
[0338] V. Results: The results are shown in Figure 2, which shows the SARS-CoV-2 proliferation curve analysis in infected Vero cells treated with test buffer or control medium. As can be seen from the figure, all four test buffers in Example 4 suppressed viral replication to a statistically significant degree for at least 24 hours compared to the untreated DMEM-2 control.
[0339] Example 6 - Insights into the Mode of Action Host: HuH7 cells (human hepatocytes) Virus: SARS-CoV-2 spike pseudotype reporter particle
[0340] I. Objective: To test the effect of buffers on preventing or reducing the viral entry / initial replication cycle. To investigate the effect of reducing the ZnCl2 concentration in the buffer (100 μM to 0.39 μM).
[0341] II. Study Design: Coronavirus entry into host cells is mediated by the spike S protein. By replacing the envelope protein in the vector virus with the spike S protein, SARS-CoV-2 spike pseudotype reporter particles were used as a model to simulate infection by SARS-CoV-2. The vector virus contains a reporter luminescence gene. By detecting luminescence in target cells, it is possible to select the ability of a buffer to neutralize the virus, i.e., the ability of a test buffer to reduce viral infection. Therefore, this experiment investigates only the early stages of infection, i.e., entry and the first replication cycle.
[0342] Dilution of buffer solution and incubation with pseudovirus: 1. In a flat-bottomed 96-well plate (ThermoFisher, #136101), two dilutions of buffers A and B from Example 4 were prepared in a total volume of 100 μl per well until the final dilution of 1 / 256 of the buffer was achieved. 2.1x10 5 RLU SARS-CoV-2 pseudotyped lentivirus particles were added to each well and incubated at 37°C for 1 hour. 3. The first column (8 control wells) received SARS-CoV-2 pseudotyped lentiviral particles and cells only (viral control), while the second column received cells only (background control).
[0343] Preparation and viral exposure of HuH7 cells: 1. Remove the culture medium from T75 containing adherent HuH7 cells and rinse the cells with PBS. 2.2 ml of trypsin was added to the cells, and the cells were returned to the incubator for 5 minutes. 3. The cells were detached and resuspended in 8 ml of FBS-containing DMEM. Microscopic confirmation was obtained that a single-cell suspension was produced by pipetting, aspirating the lower layer and dispensing the upper layer. 4. The cell concentration was measured using a cell counter. 5. Cells are incubated in DMEM to a final concentration of 4x10 5 Diluted to 1 cell / ml. 6.4x10 4 A 100 μl cell suspension containing individual cells was added to each well of a 96-well plate. 7. The plates were incubated at 37°C under 5% CO2 for 72 hours.
[0344] Evaluation of infection neutralization by buffer: 1.150 μl of culture medium / supernatant was taken from each well, and 50 μl of Steady-Glo® Luciferase Assay System (Promega) was added. 2. Luminescence / luciferase activity was measured using a CLARIOstar Plate Reader (BMG Labtech).
[0345] Analysis using Prism8: 1. Curves of relative infection rates (%) versus buffer dilution (log10 values) for pooled serum (Sigma) and positive antidote serum collected before 2016 were plotted using Prism8 (GraphPad). 2. Using a nonlinear regression (curve fitting) method, the dilution factor that neutralizes 50% was determined.
[0346] III.Results: The results are shown in Figure 3, which represents the % neutralization versus buffer dilution (log10 value). As can be seen from the figure, buffers A and B in Example 4 effectively suppressed infection of HuH7 cells with SARS-CoV-2 spike pseudotype reporter particles, even at a 256-fold dilution.
[0347] Example 7 - Synthesis Eight compositions according to the present invention were prepared as follows. Compositions A, B, and C differ in the amount of essential oils they contain (ginger oil, eucalyptus oil, basil oil, and clove oil), i.e., 2%, 1%, and 0.4% in total, respectively. Composition D is the same as composition B, but without zinc chloride. Compositions E, F, G, and H differ in the type of essential oil, with each composition containing only one oil from ginger oil, eucalyptus oil, basil oil, or clove oil. [Table 5] [Table 6] [Table 7]
[0348] Manufacturing method: Step 1: Preparation of phosphate buffer 1. KH2PO4 was dissolved in 24 ml of distilled water for injection to obtain a clear solution. 2. Add Na2HPO4 to the solution and stir to obtain a clear solution. 3. Distilled water for injection was added to bring the volume to 100 ml. 4. The pH of the buffer solution was tested and found to be in the range of 7.2 to 7.5.
[0349] Stage 2: Preparation of the aqueous phase 1. Poloxamer was dissolved in 10 ml of distilled water for injection. Then, sodium hyaluronate was added, and the mixture was swelled to obtain mixture A. 2. HPMC was swollen in 10 ml of distilled water for injection to obtain mixture B. 3. NaCl, KCl, MgCl2·6H2O, NaHCO3, xylitol, EDTA, CaCl2·2H2O, and ZnCl2 (if used) were sequentially dissolved in 20 ml of distilled water for injection to obtain mixture C.
[0350] Stage 3: Preparation and mixing of the oil phase 1. PEG400 and all the essential oils (ginger oil, eucalyptus oil, basil oil, and / or clove oil) were added together to obtain mixture D. 2. After mixing mixtures A and B together, mixture C was added to form a blend. 3. After adding mixture D to this blend, glycerol and benzalkonium chloride were added. 4. The volume was adjusted to 100 ml using the previously prepared phosphate buffer solution. 5. This mixture was homogenized at 8000-9000 rpm for 15-20 minutes. 6. The homogenized composition was filtered through a Whatman filter (11 μm size filter paper). 7. The pH of the composition was tested and found to be in the range of 7.2 to 7.7. The buffering capacity for 1M HCl was found to be 0.02. The viscosity of composition 7B was found to be 36 centipoise at 20°C. 8. The composition was dispensed into spray bottles. Five further compositions (I-M) without buffer were prepared. [Table 8]
[0351] Manufacturing method: 1. Poloxamer was dissolved in 10 ml of distilled water for injection to obtain mixture A. 2. HPMC was swollen in 10 ml of distilled water for injection to obtain mixture B. 3. Mixtures A and B were mixed together. 4. Essential oils (ginger oil, eucalyptus oil, basil oil, and / or clove oil) were added to this mixture. 5. Add distilled water for injection to bring the volume to 100 ml. 6. This mixture was homogenized at 8000-9000 rpm for 15-20 minutes. 7. The homogenized composition was filtered through a Whatman filter (11 μm size filter paper). 8. The pH of the composition was tested and found to be in the range of 6.7 to 7.0. 9. The composition was dispensed into spray bottles. Two further compositions (N and O) without buffer were prepared. [Table 9]
[0352] Manufacturing method: Stage 1: Preparation of the aqueous phase 1. Poloxamer was dissolved in 10 ml of distilled water for injection. Then, sodium hyaluronate was added, and the mixture was swelled to obtain mixture A. 2. HPMC was swollen in 10 ml of distilled water for injection to obtain mixture B. 3. NaCl, KCl, MgCl2·6H2O, xylitol, EDTA, CaCl2·2H2O, and ZnCl2 (if used) were sequentially dissolved in 20 ml of distilled water for injection to obtain mixture C.
[0353] Stage 2: Preparation and mixing of the oil phase 1. PEG400 and all the essential oils (ginger oil, eucalyptus oil, basil oil, and clove oil) were added together to obtain mixture D. 2. After mixing mixtures A and B together, mixture C was added to form a blend. 3. After adding mixture D to this blend, glycerol and benzalkonium chloride were added. 4. Distilled water for injection was added to bring the volume to 100 ml. 5. This mixture was homogenized at 8000-9000 rpm for 15-20 minutes. 6. The homogenized composition was filtered through a Whatman filter (11 μm size filter paper). 7. The composition was dispensed into spray bottles.
[0354] Example 8 - Antimicrobial / Bactericidal Assay This test was performed to evaluate the antimicrobial activity of the compositions of Examples 7B and 7C. This assay measured changes in the aerobic microbial population within a specified sampling time (30 seconds or 60 seconds) when the test specimen (compositions of Examples 7B and 7C) was present.
[0355] The test specimen (composition of Example 7B or 7C) was exposed to a known microbial population at room temperature for a specified time (30 or 60 seconds). The sample was then neutralized to eliminate its antimicrobial activity, and the viable microorganisms were counted. The percentage reduction was calculated by comparing the microbial population to that before treatment. [Table 10] [Table 11]
[0356] The test results are summarized in Tables 6 and 7. Both compositions of Examples 7B and 7C showed substantial antibacterial activity against bacteria (such as Salmonella avonii, Staphylococcus aureus, Escherichia coli, Listeria monocytogenes, and Staphylococcus epidermidis) and fungi (such as Aspergillus brasiliensis and Candida albicans).
[0357] Example 9 - Virucidal effect against SARS-CoV-2 and influenza A(H1N1) Test A This test was performed in vitro to evaluate the virucidal activity of the composition of Example 7A against SARS-CoV-2 and influenza A (H1N1). The virucidal activity of the test sample (composition of Example 7A) was tested by liquid-liquid contact of a virus solution containing the test sample. Two test concentrations of the test sample were incubated with the causative agent of a novel coronavirus (SARS-CoV-2 strain USA-WA1 / 2020) and the causative agent of influenza A (H1N1 pdm09) for 5 minutes. Subsequently, the viruses incubated with the test sample were neutralized and added to a dense layer of host cells. Viable viruses were quantified by a standard endpoint dilution assay. The endpoint titer of the sample (50% cell culture infection dose, CCID50) was determined using the Reed-Muench method, and the log reduction value (LRV) of the test sample was calculated compared to the negative (water) control (LRV < 1 indicates no virucidal activity, LRV > 1 indicates virucidal activity).
[0358] Test Design A Host cells - SARS-CoV-2: Vero E6, Influenza: MDCK Pre-incubation of test samples with the virus - 5 minutes Incubation of cells after viral infection - 5 days -SARS-CoV-2 virus stock was prepared by viral replication in Vero E6 cells. Influenza A(H1N1) virus stock was prepared by viral replication in MDCK cells. The test medium used was MEM supplemented with 10 U / mL trypsin, 1 μg / mL EDTA, and 50 μg / mL gentamicin. - The test specimen was mixed with two concentrations of virus solution (referred to as 90% and 50%) and incubated together at room temperature for 5 minutes. 90% - The test specimen and virus solution were mixed so that 90% by volume of the composition of Example 7A and 10% by volume of virus were present. 50% - The test specimen and virus solution were mixed so that 50% by volume of the composition of Example 7A and 50% by volume of virus were present. - After the contact period, the solution was neutralized by diluting it 1 / 10 in the test culture medium. - Viable viruses were quantified using a standard endpoint dilution assay. - The sample was sequentially diluted using eight 10-fold dilutions in test culture medium and added to host cells. - The plates were incubated under 5% CO2 at 37°C. - On day 5 post-infection, plates were scored for the presence or absence of viral cytopathic effect (CPE). The Reed-Muench method was used to determine the endpoint titer of the samples (50% cell culture infection dose, CCID50) and the log reduction value (LRV) of the test samples. Result A The test results are summarized in Tables 8 and 9. [Table 12] [Table 13] When tested for 5 minutes at two different concentrations, the composition of Example 7A showed virucidal activity against SARS-CoV-2 and influenza A(H1N1).
[0359] Test B This test was performed in vitro to evaluate the virucidal activity against SARS-CoV-2 of the buffered compositions of Examples 7E-7G and the unbuffered compositions of Examples 7J-7M (all of which contained only one essential oil each).
[0360] Experimental Design B Host Cell-SARS-CoV-2: Vero76 Pre-incubation of test samples with the virus - 5 minutes Incubation of cells after viral infection - 7 days -SARS-CoV-2 virus stocks were prepared by viral replication in Vero 76 cells. - The test medium used was DMEM supplemented with penicillin (100 units / mL), streptomycin (100 μg / mL), amphotericin B (0.25 μg / mL), and 2% FBS. -In Example 7, the test specimen was mixed with a virus solution to contain 90% by volume of one of the compositions from E-7G or 7J-7M and 10% by volume of virus, and incubated at room temperature for 5 minutes. - After the contact period, the solution was neutralized by diluting it 1 / 10 in the test culture medium. - Viable viruses were quantified using a standard endpoint dilution assay. - The sample was sequentially diluted in test medium using six different 10-fold dilutions and added to host cells. - The plates were incubated under 5% CO2 at 37°C. - On day 7 post-infection, plates were scored for the presence or absence of viral cytopathic effect (CPE). The Reed-Muench method was used to determine the endpoint titer of the samples (50% cell culture infection dose, CCID50) and the log reduction value (LRV) of the test samples.
[0361] Result B The test results are summarized in Table 16. [Table 14] When tested for 5 minutes in an unbuffered composition, clove oil, eucalyptus oil, ginger oil, and basil oil all showed virucidal activity against SARS-CoV-2. Furthermore, when the oils were used in a buffered composition, their virucidal activity improved.
[0362] Example 10 - In vitro protease inhibition In this study, the effects of the composition of Example 7B on the inhibition of proteases associated with COVID-19, including cathepsin L, 3CL, furin, and DPP4, were investigated using a cell-free assay. Cathepsin L mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein, thus promoting coronavirus entry into human host cells, viral-host cell endosomal membrane fusion, and viral RNA release for the next round of replication. 3C-like protease (3CLpro) is essential for SARS-CoV replication. DPP4 interacts with the spike glycoprotein S1b domain and promotes viral entry. Furin is involved in the cleavage of SARS-CoV-2 and its entry into host cells. The purified protease was incubated with the test sample (composition from Example 7B) and a positive control, and the inhibitory effect of the test sample and positive control was evaluated using the corresponding fluorescence-generating substrate.
[0363] Test design procedure -A cell-free biochemical kit from BPS Bioscience, US was used to perform a protease inhibition assay according to the manufacturer's protocol. - Positive controls (PCs) were provided in the kit. -The composition of Example 7B was diluted with the assay buffer derived from the kit to obtain the desired final concentration % of essential oil shown in Tables 10-13. - The percentage inhibition of fluorescence was determined by comparing it with the enzyme control (i.e., test sample / no positive control). [Table 15] [Table 16] [Table 17] [Table 18]
[0364] result The test results are summarized in Tables 10-13. The composition of Example 7B resulted in inhibition of 3CL, DPP4, cathepsin L, and furin protease by 16%, 18.4%, 66.7%, and 45.7%, respectively. The results showed that the composition of Example 7B resulted in significant inhibition (p<0.01 or p<0.001) of 3CL, DPP4, cathepsin L, and furin protease compared to the enzyme control.
[0365] Example 11 - Inhibition of spike S1-ACE2 interaction SARS-CoV-2 enters the human body via the spike S1 protein, which binds to ACE2 receptors present on nasal mucosa and lung cells. Inhibiting the binding of the spike S1 protein to the ACE2 receptor has been widely considered a preventive strategy against COVID-19. In this study, the effect of the composition of Example 7B on inhibiting the binding of the spike S1 protein to the ACE2 receptor was investigated using a cell-free assay with an ELISA-like colorimetric analysis kit. Different concentrations of the test material (composition of Example 7B) and a positive control were added to 96-well plates (pre-coated with rabbit Fc-tagged SARS-CoV-2 spike S1 RBD) along with an ACE2 inhibitor screening reagent and incubated. The spike inhibitor screening reagent was then added to the plates and incubated again. Finally, the plates were treated with an anti-his HRP conjugate, followed by the addition of a TMB substrate to obtain light absorption, which was measured at a wavelength of 450 nm using a spectrophotometer.
[0366] Test design procedure - Inhibition of spike S1-ACE2 interaction was investigated using a cell-free assay kit, the SARS-CoV-2 spike-ACE2 interaction inhibitor screening assay kit, from Cayman Chemical Company, US, according to the manufacturer's protocol. - Emodin was used as a positive control (PC). -The composition of Example 7B was diluted in serum-free medium to obtain essential oils of the desired final concentration % shown in Table 14. -A SARS-CoV-2 inhibitor control was used as the internal kit control (provided in the kit). - The percentage of inhibition of the spike S1-ACE2 interaction was determined by comparing it to the initial activity at 100%. [Table 19]
[0367] result The composition of Example 7B significantly inhibited spike S1-ACE2 binding by 63.9% (p<0.001) compared to the control. Based on these results, it can be concluded that the composition of Example 7B inhibits the binding of the spike S1 protein to the ACE2 receptor.
[0368] Example 12 This example was carried out to demonstrate that BES (used in Example 4) can be substituted with taurine in the buffer composition of the present invention. Buffer solutions A to F were prepared by stirring the components listed in Table 15 in 1 L of ultrapure water (ATSM type I, 18.2 MΩ / cm at 25°C). [Table 20] It was revealed that all six buffers A to F are buffer compositions having a pH suitable for use in the treatment of the present invention.
[0369] Example 13 - Manufacturing Example Thiamine pyrophosphate chloride was prepared as a 0.4 mg / mL stock solution in purified water free of Milli-Q endotoxin and stored frozen in a dark glass vial. Choline chloride was prepared as a 17.45 mg / mL stock solution in purified water free of Milli-Q endotoxin and stored frozen in a glass vial. Human recombinant insulin was prepared as a 0.5 mIU / mL stock solution in purified water free of Milli-Q endotoxin, acidified to pH 2.4 with 0.1 N hydrochloric acid, and stored frozen in a glass vial.
[0370] In the following preparations, Milli-Q endotoxin-free purified water was used throughout for initial stirring and final dilution.
[0371] For preparation, a stainless steel container was filled with 8 liters of MilliQ endotoxin-free purified water, and the following ingredients were added in the following order while constantly stirring: 642.96 g sodium chloride, 37.28 g potassium chloride, 18.38 g calcium chloride dihydrate, 9.14 g magnesium chloride hexahydrate, 1.363 g zinc chloride, 106.61 g N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), and, if necessary, 1.84 mg of thiosulfate. Amine pyrophosphate chloride (using 4.6 mL of stock solution), 0.9899 g L-carnitine, 0.1396 g choline chloride (using 8 mL of stock solution), 1.013 g glycerol, and, if necessary, 2.8 mIU human recombinant insulin (using 5.6 mL of stock solution), 0.310 g L-sodium aspartate, 180.2 g anhydrous D-glucose, 5.07 g L-sodium glutamate, and 5.84 g L-glutamine. After stirring the mixture until completely dissolved, a final volume of 10 liters was prepared by adding purified water free of Milli-Q endotoxin. The solution was passed through a bacterial filter (0.2 μm Zaltobran PH) and placed in a 100 mL sterile, sealed glass bottle. This solution is 10x the concentration of the solution to be used. The concentrate can be stored in the dark at 3-8°C for up to 5 years.
[0372] For use, 100 mL of the concentrate was diluted with 900 mL of double-deionized or Milli-Q endotoxin-free purified water, and 2.1 g of endotoxin-free sodium bicarbonate was added to make 1 liter. This was then stored at 8-10°C until use. For storage stability, it is preferable not to add sodium bicarbonate to the concentrate before storage.
[0373] Example 14 - Ex vivo permeability test Eugenol is the active ingredient in clove oil and basil oil. Ex vivo permeability tests were conducted to confirm whether eugenol permeates through the nasal mucosa of goats. The goat nasal mucosa was retained in phosphate buffer pH 6.4, after which the cartilage was carefully removed. The nasal mucosa was stabilized in a Franz-type diffusion cell (Logan Instrument Corporation, NJ USA) containing phosphate buffer pH 6.4 in both the donor and acceptor compartments. Compositions 7B, 7D, 7N, or 7O (3 ml) were dispensed into the donor compartment. Eugenol was added in a 0.15 cm solution. 2 The sample was allowed to permeate through the area of the sample. At intervals of 5 minutes to 8 hours, 1 ml of sample was removed from the acceptor compartment, an equal volume of PBS pH 6.4 was added, and the sink conditions were maintained. The sample was analyzed by GC-MS. The amount of eugenol that permeated through the nasal mucosa was calculated using the following formula:
number
[0374] Results: Ex vivo permeability of eugenol through the goat nasal mucosa after 8 hours was found to be 94% for composition 7B, 84% for composition 7N (without buffer), 75% for composition 7D (without zinc ions), and 72% for composition 7O (without both buffer and zinc ions). This indicates that both buffer and zinc ions increase eugenol permeability. It should be understood that the present invention is described above for illustrative purposes only. The examples are not intended to limit the scope of the invention. Various modifications and embodiments can be implemented without departing from the scope and spirit of the invention as defined solely by the following claims.
[0375] Sequence ID 1 is the following sequence: Xaa can be any naturally occurring amino acid: [Table 21]
Claims
1. A composition comprising one or more of clove oil, eucalyptus oil, basil oil, ginger oil, an extract or component of any of these, or a combination thereof, for use in the treatment, prophylactic treatment or amelioration of an airborne viral infection or for use in reducing or preventing viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection in said subject.
2. The composition of claim 1 further comprising a buffer.
3. 1. An aqueous composition comprising: (i) a 1 to 500 mmol / L buffer; and (ii) An aqueous composition comprising 0.1 to 200 g / L of an essential oil or an extract or component thereof having antiviral, antibacterial or antifungal activity.
4. 4. The composition of claim 3, wherein the essential oil is selected from clove oil, eucalyptus oil, basil oil, ginger oil, saffron oil, hemp oil, tea tree oil, black seed oil, an extract or component of any of these, or a combination thereof.
5. (A) The extract or component of the essential oil contains any one of eugenol, zingiberene, eucalyptol, gensenone, ursolic acid, caryophyllene, estragole, 1,8-cineole, camphor, thymol, eugenol epoxide, apigenin, linalool, rosmarinic acid, 6-gingerol, 6-shogaol, gingerenone A, crocetin, crocin, picrocrocin, safranal, caffranone, tetrahydrocannabinol, cannabidiol (or a metabolite thereof). 7-hydroxycannabidiol), cannabinol, tetrahydrocannabivarin, terpinen-4-ol, terpinolene, α-terpineol, thymoquinone, α-curcumene, β-sesquiphellandrene, α-farnesene, α-phellandrene, β-phellandrene, camphene, β-bisabolene, α-terpinene, γ-terpinene, p-cymene, α-pinene, or mono- or polyunsaturated fatty acids such as palmitoleic acid, heptadecenoic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, arachidonic acid, or erucic acid, and / or (B) the essential oil, or an extract or component thereof, has antiviral activity; The composition according to any one of claims 1 to 4.
6. The buffer solution is (A) contains bicarbonate ions or their equivalent; and / or (B) comprising, consisting of, or consisting essentially of (i) Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acid, peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or combinations thereof, and (ii) bicarbonate ion or its equivalent; and / or (C) comprising, consisting of, or consisting essentially of: (i) 1-100 mmol / L Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acid, peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or combinations thereof; and (ii) 21-35 mmol / L bicarbonate ion or its equivalent; and / or (D) comprising, consisting of, or consisting essentially of: (i) one or more phosphates, and (ii) bicarbonate ions; and / or (E) comprising, consisting of, or consisting essentially of KH2PO4, Na2HPO4, and NaHCO3; The composition according to any one of claims 2 to 5.
7. (A) further containing 0.1 to 200 μmol / L of zinc ions, and / or (B) further comprising 1 to 100 μmol / L of transferrin and / or iron ions; and / or (C)(i) a 1 to 500 mmol / L buffer; (ii) 0.1 to 50 g / L of clove oil or an extract or component thereof; (iii) 0.1 to 50 g / L of eucalyptus oil or an extract or component thereof; (iv) 0.1 to 50 g / L of basilisk oil or an extract or component thereof; and (v) 0.1 to 50 g / L of ginger oil or an extract or component thereof and / or (D)(i) a 1 to 500 mmol / L buffer; (ii) 0.1 to 200 μmol / L of zinc ions; (iii) 0.1 to 50 g / L of clove oil or an extract or component thereof; (iv) 0.1 to 50 g / L of eucalyptus oil or an extract or component thereof; (v) 0.1 to 50 g / L of basilisk oil or an extract or component thereof; and (vi) 0.1 to 50 g / L of ginger oil or an extract or component thereof and / or (E)(i) one or more phosphoric acids at 25 to 250 mmol / L; (ii) 1 to 45 mmol / L bicarbonate ion; (iii) 0.1-10 g / L of clove oil or an extract or component thereof; (iv) 0.1 to 10 g / L of eucalyptus oil or an extract or component thereof; (v) 0.1 to 10 g / L of basilisk oil or an extract or component thereof; and (vi) 0.1 to 10 g / L of ginger oil or an extract or component thereof and / or (F)(i) one or more phosphoric acids at 25 to 250 mmol / L; (ii) 1 to 45 mmol / L bicarbonate ion; (iii) 0.1 to 50 μmol / L zinc ion; (iv) 0.1-10 g / L of clove oil or an extract or component thereof; (v) 0.1 to 10 g / L of eucalyptus oil or an extract or component thereof; (vi) 0.1 to 10 g / L of basilisk oil or an extract or component thereof; and (vii) 0.1 to 10 g / L of ginger oil or an extract or component thereof and / or (G)(i) calcium ions and magnesium ions in a molar concentration ratio of 5:1 to 1:1, said calcium ions being 0.1 to 2.5 mmol / L; (ii) 2.5 to 20 mmol / L potassium ion; (iii) 96 to 126 mmol / L of chloride ion; and (iv) 100 to 300 mmol / L sodium ion and / or (H) further comprising one or more additional ingredients selected from NaCl, KCl, MgCl2, xylitol, EDTA, CaCl2, glycerol, HPMC, PEG400, poloxamer 188, benzalkonium chloride and sodium hyaluronate; and / or (I) (i) 1-100 mmol / L (preferably 1-12 mmol / L) of Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acid, peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or combinations thereof; (ii) calcium ions and magnesium ions in a molar concentration ratio of 5:1 to 1:1, the calcium ions being 0.1 to 2.5 mmol / L; (iii) 21 to 35 mmol / L bicarbonate ion or its equivalent; (iv) 2.5 to 6.2 mmol / L potassium ion; (v) 96 to 126 mmol / L of chloride ion; and (vi) 100 to 150 mmol / L sodium ion and / or (J)(i) 1-100 mmol / L (preferably 1-12 mmol / L) of Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acid, peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or combinations thereof; (ii) calcium ions and magnesium ions in a molar concentration ratio of 5:1 to 1:1, the calcium ions being 0.1 to 2.5 mmol / L; (iii) 21 to 35 mmol / L bicarbonate ion or its equivalent; (iv) 2.5 to 6.2 mmol / L potassium ion; (v) 96 to 126 mmol / L chloride ion; (vi) 100 to 150 mmol / L sodium ion; and (vii) 0.1 to 200 μmol / L of zinc ion and / or (K)(i) 1-100 mmol / L (preferably 1-12 mmol / L) of Good's buffer, aminosulfonic acid, aminosulfinic acid, phosphoric acid, phosphorous acid, heteroaryl, phenolic acid, amino acid, peptide, peptide equivalent, polymer buffer, urea, ionic liquid buffer, or combinations thereof; (ii) calcium ions and magnesium ions in a molar concentration ratio of 5:1 to 1:1, the calcium ions being 0.1 to 2.5 mmol / L; (iii) 21 to 35 mmol / L bicarbonate ion or its equivalent; (iv) 2.5 to 6.2 mmol / L potassium ion; (v) 96 to 126 mmol / L chloride ion; (vi) 100 to 150 mmol / L sodium ions; (vii) 1 to 100 μmol / L transferrin; and (viii) 1 to 100 μmol / L of iron ion and / or (L) further comprising an antibiotic, an emulsifier and / or an antioxidant; The composition according to any one of claims 1 to 6.
8. (A) is an emulsion or contains microdroplets, and / or (B) having a pH of 6.7 to 7.9 at a temperature of 37° C.; The composition according to any one of claims 1 to 7.
9. The composition, (A) by inhalation into the oral cavity, upper respiratory tract, lower respiratory tract, nasal cavity, pharynx, larynx, trachea, bronchi or lungs; and / or (B) administration by inhalation, nebulizer, nasal spray, oral spray, bronchial spray, nasal drops, nasal wash, nasal irrigation, neti pot, nasal tamponade, gargling or rinsing, or in the form of a cream, gel, emulsion, or ointment; and / or (C) by application to a mask or other face covering, or by use in a container configured to bubble an oxygen-containing gas through the composition prior to inhalation of the gas by the subject, or by diffusing or spraying into the air prior to inhalation of the air by the subject; and / or (D) for use in the treatment, prophylactic treatment or amelioration of an airborne viral infection, or in reducing or preventing viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection; and / or (E) Use in the treatment, prophylactic treatment, or amelioration of an airborne viral infection, or in reducing or preventing viral replication in a subject infected with or exposed to an airborne virus capable of causing an airborne viral infection, wherein the airborne viral infection is selected from the group consisting of: (i) a coronavirus (including a coronavirus selected from MERS-CoV, SARS-CoV, and SARS-CoV-2), an influenza virus (including an influenza virus selected from influenza A virus, influenza B virus, influenza C virus, and parainfluenza virus), a rhinovirus, a measles virus, a rabies ... (ii) caused by an RNA virus, such as the human respiratory syncytial virus, mumps virus, rubella virus, or human respiratory syncytial virus, or (ii) caused by a DNA virus, such as parvovirus B19, adenovirus, adeno-associated virus, herpes virus (including a herpes virus selected from varicella zoster virus (VZV or HHV-3), Epstein-Barr virus (EBV or HHV-4), human herpes virus 6 (HHV-6A and HHV-6B), and human herpes virus 7 (HHV-7)), polyoma virus (including a polyoma virus selected from BK polyoma virus and WU polyoma virus), or smallpox virus. The composition according to any one of claims 1 to 8, which is suitable for
10. A process for preparing a composition according to any one of claims 1 to 9, comprising mixing all the ingredients with a solvent (preferably water), optionally bringing to the desired volume, optionally filtering, and optionally storing in a sealed container. (A) comprising water and all of the ingredients and capable of being diluted with water to form the composition of any one of claims 1 to 9; or (B) water and all components other than bicarbonate ion or its equivalent and their counter cations, and is dilutable with water containing said bicarbonate ion or its equivalent and their counter cations to form the composition of any one of claims 1 to 9. A concentrate for the preparation of a composition according to any one of claims 1 to 9.
12. 10. Use of the composition of any one of claims 1 to 9 in the manufacture of a medicament for the treatment, prophylactic treatment or amelioration of an airborne viral infection in a subject, or for the reduction or prevention of viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection in a subject, optionally wherein the airborne viral infection is selected from the group consisting of: (i) a coronavirus (including a coronavirus selected from MERS-CoV, SARS-CoV, and SARS-CoV-2), an influenza virus (including an influenza A virus, influenza B virus, influenza C virus, and a parainfluenza virus), (ii) an RNA virus, such as human respiratory syncytial virus, human rhinovirus, measles virus, mumps virus, rubella virus, or human respiratory syncytial virus, or (ii) a DNA virus, such as parvovirus B19, adenovirus, adeno-associated virus, herpes virus (including a herpes virus selected from varicella zoster virus (VZV or HHV-3), Epstein-Barr virus (EBV or HHV-4), human herpes virus 6 (HHV-6A and HHV-6B), and human herpes virus 7 (HHV-7)), polyoma virus (including a polyoma virus selected from BK polyoma virus and WU polyoma virus), or smallpox virus.
13. 1. A method for reducing a risk of viral infection from an airborne virus in a subject, comprising: (A) applying a composition according to any one of claims 1 to 9 to a mask or other facial covering; or (B) bubbling an oxygen-containing gas through a composition according to any one of claims 1 to 9 prior to inhalation of the gas by the subject; or (C) diffusing or spraying a composition according to any one of claims 1 to 9 into the air prior to inhalation of the air by the subject. A method comprising: (A) a composition according to any one of claims 1 to 9, or (B)(i) A concentrate according to claim 11(A) and (ii) water, or (C)(i) 11(B) comprising the concentrate of claim 11(B) and (ii) water containing bicarbonate ions or their equivalents and their counter cations. A spray, inhalant, nebulizer, nasal spray, oral spray, bronchial spray, nasal drops, nasal wash, nasal irrigator, neti pot, nasal tampon, mouthwash or gargle, container, cream, gel, emulsion, or ointment, comprising:
15. A mask or other facial covering coated with or impregnated with a composition according to any one of claims 1 to 9.
16. A method for cleaning an object, comprising applying to said object a composition according to any one of claims 1 to 9.
